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Abstract 48 
Metabolomics is a potentially powerful tool for identification of biomarkers associated with 49 
lifestyle exposures and risk of various diseases. This is the rationale of the “meeting-in-the-50 
middle” concept, for which an analytical framework was developed in this study. In a nested 51 
case-control study on hepatocellular carcinoma (HCC) within the European Prospective 52 
Investigation into Cancer and nutrition (EPIC), serum 1H NMR spectra (800 MHz) were 53 
acquired for 114 cases and 222 matched controls. Through Partial Least Square (PLS) 54 
analysis, 21 lifestyle variables (the “predictors”, including information on diet, anthropometry 55 
and clinical characteristics) were linked to a set of 285 metabolic variables (the “responses”). 56 
The three resulting scores were related to HCC risk by means of conditional logistic 57 
regressions. The first PLS factor was not associated with HCC risk. The second PLS 58 
metabolomic factor was positively associated with tyrosine and glucose, and was related to a 59 
significantly increased HCC risk with OR= 1.11 (95%CI: 1.02, 1.22, p=0.02) for a 1-SD 60 
change in the responses score, and a similar association was found for the corresponding 61 
lifestyle component of the factor. The third PLS lifestyle factor was associated with lifetime 62 
alcohol consumption, hepatitis and smoking, and had negative loadings on vegetables intake. 63 
Its metabolomic counterpart displayed positive loadings on ethanol, glutamate and 64 
phenylalanine. These factors were positively and statistically significantly associated with 65 
HCC risk, with 1.37 (1.05, 1.79, p=0.02) and 1.22 (1.04, 1.44, p=0.01), respectively. Evidence 66 
of mediation was found in both the second and third PLS factors, where the metabolomic 67 
signals mediated the relation between the lifestyle component and HCC outcome. This study 68 
devised a way to bridge lifestyle variables to HCC risk through NMR metabolomics data. 69 
This implementation of the “meeting-in-the-middle” approach finds natural applications in 70 
settings characterized by high-dimensional data, increasingly frequent in the –omics 71 
generation. 72 
4 
 
Keyword: partial least square, lifestyle factors, metabolomics, hepatocellular carcinoma, 73 
meeting-in-the-middle, molecular epidemiology.  74 
5 
 
Introduction 75 
Metabolomic profiles from blood and other biological samples collected from large-76 
scale epidemiologic studies are increasingly being investigated [1], following recent 77 
developments in nuclear magnetic resonance (NMR) and mass spectrometry (MS) enabling 78 
the assessment of metabolic profiles for large numbers of individuals. As a result, 79 
metabolomic data is gradually playing a key part in clinical and observational studies; and 80 
new statistical methodologies [2] are increasingly being sought to explore insights into 81 
pathological processes that metabolomics may provide in order to better understand 82 
determinants of disease development. These approaches explore a variety of etiological 83 
hypotheses; however they usually focus on one aspect at a time, combining metabolomics 84 
with either epidemiologic/phenotypic data on lifestyle exposures [3] or with disease outcomes 85 
[4,5]. The main aim of this work is to jointly use all aspects that are potentially informative to 86 
apprehend the contrivances of disease development.  87 
Metabolomic data offers the opportunity to identify signatures and biomarkers 88 
associated with environmental exposures and the risk of a disease. Prospective studies are 89 
conceptually suitable for this purpose, since they rely on biological samples collected before 90 
disease onset, and are thus marginally influenced by metabolic changes due to processes of 91 
disease development. In this scenario, the “meeting-in-the-middle” (MITM) approach [6] has 92 
been conceived as a research strategy to identify biomarkers that are related to specific 93 
exposures and that are, at the same time, predictive of disease outcome. Finding this overlap 94 
between exposure and disease of “intermediate” biomarkers can potentially disclose useful 95 
information on the exposure-to-disease pathway, and may serve as an objective risk exposure 96 
measure, ultimately allowing the identification of a targeted prevention scheme. The MITM 97 
was previously implemented as a proof of concept in a case-control study nested within a 98 
cohort of healthy individuals [7], where a list of putative intermediate 1H NMR biomarkers 99 
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linking exposure to dietary compounds, mainly micro- and macronutrients, and disease 100 
outcomes (colon and breast cancer) were investigated.  101 
In this study we extend previous attempts to model the MITM by fully integrating 102 
metabolomics, lifestyle and disease risk in a single analytical framework. A strategy was 103 
developed to simultaneously investigate a broad range of metabolites and lifestyle variables 104 
with a partial least square (PLS) regression model [8]. The resulting scores were related to the 105 
risk of hepatocellular carcinoma (HCC), in a case-control study nested within the European 106 
Prospective Investigation into Cancer and nutrition (EPIC). HCC is the most frequent primary 107 
form of cancer affecting the liver, an organ that plays a critical role in many metabolic 108 
pathways [9]. HCC is a disease with multifactorial origins embracing lifestyle and dietary 109 
exposures whose intersection may reveal metabolomic signals [10] relevant to cancer onset. 110 
The system of relationships between metabolomic profiles and lifestyle factors in relation to 111 
HCC was evaluated by means of mediation analysis. The methodological challenges 112 
characterizing the analysis of large and complex metabolomic datasets are described and 113 
discussed. 114 
Methods 115 
EPIC design. The European Prospective Investigation into Cancer and nutrition (EPIC) is a 116 
large cohort established to investigate the association of diet, lifestyle and environmental 117 
factors with cancer incidence and other chronic disease outcomes. Between 1992-2000, over 118 
520,000 participants aged 20-85 years, were recruited from 23 centers in 10 Western 119 
European countries including Denmark, France, Germany, Greece, Italy, Norway, Spain, 120 
Sweden, The Netherlands and the United Kingdom [11].  The design, rationale and methods 121 
of the EPIC study including information on dietary assessment methodology, blood collection 122 
protocols and follow-up procedures were previously detailed [11].   123 
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Between 1992 and 1998, standardized lifestyle data, anthropometric measures and biological 124 
samples were collected at recruitment, prior to onset of any disease [11]. Validated country-125 
specific questionnaires ensuring high compliance were used to measure diet over the previous 126 
12 months [12]. Blood samples are stored at the International Agency for Research on Cancer 127 
(IARC, Lyon, France) in -196˚C liquid nitrogen for all countries, exceptions being Denmark 128 
(nitrogen vapour,-150˚C) and Sweden (freezers, -80˚C).  129 
The nested case-control study. The present study focused on data with available sera samples 130 
from a nested case-control study in EPIC on hepatocellular carcinoma (HCC) [13]. Cases of 131 
HCC were identified from all participating EPIC centres except for Norway and France 132 
(n=117) from recruitment (1993-1998) up to 2007. Two controls (n=232) were selected for 133 
each case from all cohort members alive and free of cancer (except non-melanoma skin 134 
cancer) by incidence-density sampling and were matched on age at blood collection (±1 year), 135 
sex, study centre, date (±2 months), time of the day at blood collection (±3 hours) and fasting 136 
status at blood collection (<3, 3-6, >6 hours); among women, additional matching criteria 137 
included menopausal status (pre-, peri-, post-menopausal) and hormone replacement therapy 138 
(HRT) use at time of blood collection (yes/no). In the present study, cases and controls were 139 
both included in the analyses as the subjects were all cancer-free at blood collection. Out of 140 
the total 349 subjects, 7 subjects (3 cases and 4 controls) had too little serum volume for 141 
NMR spectral acquisition with sufficient sensitivity; 6 additional control subjects were 142 
excluded following the exclusion of their corresponding case subject. The final analysis 143 
included 114 HCC cases and 222 matched controls of which 108 case–control sets with two 144 
matched control subjects and 6 sets with one matched control subject. 145 
NMR spectra acquisition. Sera were processed using standard procedure for 1H NMR 146 
metabolic measurement and profiling protocols [14]. Details on the sera sample preparation as 147 
well as NMR data acquisition and processing have been described elsewhere [15]. In brief, 148 
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each spectrum was reduced to 8,500 bins of 0.001 ppm width over the chemical shift range of 149 
0.5 to 9 ppm. Spectra were normalized to total intensity, centred and Pareto scaled, and 150 
additionally normalized for batch-effects using the batch profiling calibration method [16]. 151 
After removal of the structured noise (characterized by a specific mean and standard 152 
deviation) located in a well-known noise region (8.5-9ppm) and variables with identical 153 
characteristics, the statistical recoupling of variables (SRV) [17], a bucketing procedure, was 154 
applied to the metabolomic spectra. The SRV procedure identifies clusters of variables with 155 
respect to the ratio of covariance and correlation between consecutive variables along the 156 
chemical shift axis, allowing the restauration of the spectral dependency and the recovery of 157 
complex NMR signals corresponding to potential physical, chemical or biological entities. 158 
More details on the SRV procedure are available in the Mathematical Appendix. This 159 
permitted a reduction of the number of NMR variables from 8,500 bins to 285 clusters of 160 
variables corresponding to reconstructed peak entities which constituted the Y-set of 161 
metabolic variables. All steps to obtain the data were done without knowledge of the case-162 
control status of the subjects. Quality control (QC) samples were included to ensure 163 
reproducibility of the NMR data acquisition. 164 
Metabolite identification. The assignment of NMR signals observed in the 1H one-165 
dimensional fingerprints to metabolites has been achieved by the analysis of additional 2D 166 
NMR experiments 1H-13C HSQC and 1H-1H TOCSY obtained on a subset of representative 167 
samples (one control and one case). The measured chemical shifts were compared to 168 
reference shifts of pure compounds using HMDB [18], MMCD [19] and ChenomX, 169 
(ChenomX NMR suite, ChenomxInc, Edmonton, Canada) databases. 170 
Lifestyle variables. The predictors (what will be referred to later on as the X-set) included 13 171 
dietary variables from main EPIC food groups compiled from validated country-specific food 172 
frequency questionnaires (FFQ) [11,20] (potatoes and other tubers; vegetables; legumes; 173 
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fruits, nuts and seeds; dairy products; cereal and cereal products; meat and meat products; fish 174 
and shellfish; egg and egg products; fat; sugar and confectionary; cakes and biscuits; non-175 
alcoholic beverages), alcohol average lifetime intake (continuous, g/day), anthropometric 176 
measures including body mass index (continuous, kg/m2) and height (continuous, cm) that 177 
were measured by trained interviewers in the majority of participants [11], highest level of 178 
education achieved (categorical: none or primary school completed, technical/professional 179 
school, secondary school, longer education (incl. university degree), unspecified), smoking 180 
status (categorical: never, former, current smoker, unknown), a measure of physical activity 181 
(continuous, metabolic equivalents of task (MET)/h), hepatitis status (yes/no, from biomarker 182 
measures of HBV and HCV seropositivity [ARCHITECT HBsAg and anti-HCV 183 
chemiluminescent microparticle immunoassays; Abbott Diagnostics, France]) and baseline 184 
self-reported diabetes status (yes/no). Descriptive information on these variables can be found 185 
in Supplementary table 1. 186 
Statistical analysis 187 
PC-PR2 analysis. Principal component partial R-square (PC-PR2) was primarily used to 188 
identify and quantify sources of systematic variability within metabolomic data [15]. PC-PR2 189 
combines aspects of principal component analysis (PCA) and the R2partial statistic in multiple 190 
linear regression, and allows for (some) inter-correlation between the explanatory variables 191 
under scrutiny [15]. In short, PCA is performed on the 285 clusters of 1H NMR variables and 192 
a number of components is retained explaining an amount of total variability above a 193 
designated threshold (here, 80%). Then, multiple linear regression models are fitted where 194 
each component’s variability is explained in terms of relevant covariates, e.g. specific 195 
characteristics of samples like country of origin, smoking status, laboratory treatment, etc. For 196 
each given component, the R2partial statistic is computed for all covariates, quantifying the 197 
amount of variability each independent variable explains, conditional on all other covariates 198 
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included in the model. Finally, an overall R2partial is calculated as a weighted average for every 199 
covariate, using the eigenvalues as components’ weights. Mathematical details pertaining to 200 
the PC-PR2 method are described elsewhere [15]. 201 
In this study, PC-PR2 was applied to the 285 clusters of NMR variables, whereas the 202 
explanatory variables examined for systematic variability were NMR batch, country of origin, 203 
sex, age at blood collection, serum clot contact time (centrifugation at the day of blood 204 
collection d, or the following day, d+1), length of freezing time (<= 15 vs. >15 years), and 205 
fasting status at blood collection (< 3, 3-6, > 6 hours). With the similar motivation of 206 
identifying sources of variability within lifestyle data, a similar PC-PR2 analysis was applied 207 
to the 21 lifestyle factors; the examined covariates for systematic variability were country of 208 
origin, sex and age at recruitment. For both metabolomics and lifestyle data, residuals on the 209 
variable accounting for most variability, identified through PC-PR2 analyses, were computed 210 
in a series of univariate linear regression models [21] and were used in the subsequent PLS.  211 
PLS analysis. A PLS model was used to relate lifestyle variables to metabolomic profiles. 212 
PLS is a multivariate technique that generalizes features of PCA and multiple linear 213 
regression. PLS iteratively extracts linear combinations of, in turn, predictors (the X-set) and 214 
responses (the Y-set), which in this study, were lifestyle variables and metabolomic profiles, 215 
respectively. First, components or latent factors are extracted allowing a simultaneous 216 
decomposition of the X- and Y-sets, in order to maximize their covariance [22]. The factors 217 
extracted from the predictors’ set are orthogonal. Computational details of PLS are described 218 
in the Mathematical Appendix. As a standard step for the PLS algorithm, the X- and Y-sets 219 
were centered and standardized for the analysis and a simple expectation-maximization (EM) 220 
algorithm, adapted from the PLS kernel algorithm [23,24], was used to compute covariance 221 
matrices when missing values were present in the lifestyle data. This was done as follows: a 222 
first pass of PLS was computed filling in the missing values by the average of the non-223 
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missing values for each corresponding variable. A second pass was then performed whereby 224 
the missing data were assigned their predicted values based on the first model, and the PLS 225 
regression is recomputed. 226 
Then, a seven-fold cross validation analysis was carried out to select the number h of 227 
significant PLS factors to retain [8] (see Mathematical appendix).This was achieved by 228 
splitting the data into seven groups of observations. In turn, each group of observations was 229 
considered as the test set, whilst the other six were the training sets, used to perform PLS 230 
analysis. A measure of PLS performance was determined for each step through the predicted 231 
residual sum of squares (PRESS) statistic, whereby the predicted values in the test set, the Ỹh 232 
matrix, based on the X-components estimated through the model in the training set, were 233 
compared to the observed responses, the Y matrix. This comparison is quantified by the 234 
squared Euclidean distance between these two matrices. In turn for an increasing number h of 235 
components, the process is iterated seven times, until each group of observations serves as a 236 
test set. Eventually, the number h of selected PLS factors is the one minimizing the PRESS 237 
statistic. 238 
For each PLS factor, loadings were computed for the lifestyle (X-set) and the NMR (Y-set) 239 
variables. The loadings, i.e. coefficients quantifying the contribution of each original variable 240 
to the PLS factor, were used to characterize the various factors. As the analysis involved 241 
many variables in the X-set and, particularly, in the Y-set, the interpretation focused primarily 242 
on variables with loading values lower than the 10th percentile and larger than the 90th 243 
percentile for the X variables, and lower than the 5th and larger than the 95th percentiles for the 244 
Y variables, that were deemed the most significant contributors to the PLS factor.  245 
Logistic regression analysis. Last, scores of each PLS factor were related to HCC risk in 246 
conditional logistic regression models to compute HCC odds ratios (ORs) and associated 95% 247 
confidence intervals (95% CI) where ORs express the change in HCC risk associated to one 248 
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standard deviation (1-SD) increase in the score. Models were adjusted for C-reactive protein 249 
concentration, alpha-fetoprotein concentration and for a composite score indicative of liver 250 
damage. The score summarizes the number of abnormal values of circulating enzymes 251 
measured in the hepatic tissue in six liver function tests (alanine aminotransferase >55 U/L, 252 
aspartate aminotransferase >34 U/L, gamma-glutamyltransferase: men>64 U/L and 253 
women>36 U/L, alkaline phosphatase >150 U/L, albumin<35 g/L, total bilirubin>20.5 254 
μmol/L; cut-points were provided by the clinical biochemistry laboratory that conducted the 255 
analyses and were based on assay specifications) [25]. These biomarkers were measured on 256 
the ARCHITECT c Systems™ and the AEROSET System (Abbott Diagnostics) using 257 
standard protocols. Laboratory analyses were performed at the Centre de Biologie République 258 
laboratory, Lyon, France. These adjustments were deemed necessary to address potential 259 
confounding stemming from metabolic disorders, inflammation or underlying liver 260 
dysfunction [25–28]. Adjustments for total dietary fibre, vitamin D, calcium and iron intakes 261 
(continuous) were evaluated but not retained in the final models for lack of confounding 262 
exerted by these variables. The receiver operating characteristic (ROC) curve and the 263 
associated area under the curve (AUC) were determined from conditional logistic regressions 264 
to evaluate the predictive performance of PLS models. AUC values were computed for 265 
conditional logistic models including progressively the PLS scores, separately for lifestyle 266 
and metabolomic factors (as shown in Table 4, column 1). The sensitivity, specificity and 267 
accuracy were calculated for a cut-off point, selected as the minimal distance between the 268 
ROC curve and the upper left corner of the diagram [29,30]. The corrected positive predictive 269 
value (PPV), taking into account the nested case-control design [31,32] was computed by 270 
including the prevalence of HCC in the EPIC population(π= 0.0004), computed over a 7-year 271 
period (1992-2010) where 191 HCC cases were ascertained from a total of 477,206 272 
participants included for case identification after relevant exclusions [33]. The AUC 273 
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unavoidably increases with the number of covariates added to the conditional logistic model. 274 
To address this issue, a resampling scheme was devised to compute an objective/ unbiased 275 
estimate of the AUC, inspired by the work of Uno et al [34]. For each one of the 1000 drawn 276 
bootstrap samples, a 10-fold cross-validation was performed, repeated ten times to remove 277 
variation due to random partitioning of data and to yield more stable estimates. The predicted 278 
values from each of the conditional logistic models in the training set were used to derive 279 
AUC values in the test set. The 2.5th and 97.5th percentile values made up the 95% confidence 280 
intervals.  281 
Sensitivity analyses. A sensitivity analysis was performed by running PLS on data excluding 282 
sets where cases were diagnosed within the first two years of follow-up. The model was 283 
conducted on 271 observations (92 cases, 179 controls), to investigate the performance of the 284 
PLS model, ruling out potential reverse causation. The metabolomic profiles of HCC cases 285 
diagnosed within two years from enrolment could reflect the presence of the tumour rather 286 
than informing about tumour aetiology. The variable importance in the projection (VIP) 287 
statistic was used to facilitate the comparison of the sensitivity analysis with the main 288 
analysis. The VIP expresses the explanatory power of a predictor variable X across all 289 
response variables Y (see Mathematical Appendix). 290 
Mediation analysis. The mediating role of the Y-scores in the association between lifestyle 291 
profiles and HCC risk was assessed. Separately for each extracted combination of lifestyle 292 
and metabolomic PLS factors, mediation analyses were performed with the ‘paramed’ Stata 293 
function that allows for exposure-mediator interaction based on Valeri and VanderWeele’s 294 
work [35]. Briefly, mediation was computed using a Baron and Kenny approach adapted to 295 
dichotomous outcomes [36], where two models were specified. In the mediator model, the 296 
mediator (the Y-score) was linearly regressed on the exposure (the X-score), while in the 297 
outcome model the exposure (X-score) and the mediator (Y-score) were related to the HCC 298 
14 
 
indicator in unconditional logistic regressions. Both models accounted for the concentration 299 
of C-reactive protein, alpha-fetoprotein and the composite score of liver damage, and 300 
additionally accommodated the other extracted metabolic profiles (Y-scores) to control for 301 
mediator-outcome confounders that may occur when estimating the Natural Indirect Effect 302 
(NIE) [35]. As the outcome (HCC) is rare, direct and indirect effects can be estimated taking 303 
into account the case-control design. This is done by using the same formulas for the effects, 304 
while running the mediator regression only for the controls [36]. As mediation packages do 305 
not yet accommodate conditional logistic models, the outcome and the mediator models, 306 
which were accommodated in unconditional logistic regressions, were adjusted for center and 307 
age at blood collection for sake of consistency with previous steps of the analysis.  308 
Statistical analyses were performed using R [37] and SAS [38] in general, with the following 309 
packages for specific purposes: PROC PLS in SAS 9.4 for PLS analyses, ‘paramed’ in Stata 310 
12 [39] for mediation analyses, ‘OptimalCutpoints’ in R for ROC-related assessments.  311 
The different steps of the analytical framework developed in this study to model the MITM 312 
are presented in Figure 1.  313 
Results 314 
In the PC-PR2 analyses, a total of 17 and 14 principal components were retained to 315 
explain an amount of total variability exceeding 80% in metabolomics and lifestyle data 316 
respectively. Figure 2 shows that the ensemble of explanatory variables accounted for 19.4% 317 
and 26.7% of total variance, respectively in metabolomics and lifestyle data, of which the 318 
highest contributor was ‘country of origin’ with consistently 8% and 22%. . Major sources of 319 
variation in the Y-set displaying large R2partial value were country of origin (8.3%), NMR 320 
batch (4.0%) and fasting status at blood collection (1.6%). In the X-set, country of origin 321 
(22.6%) and sex (5.1%) showed the highest contributions. As PC-PR2 analysis showed that 322 
15 
 
‘country of origin’ accounted for about 8% of the variability within the metabolomic data, and 323 
22% in the lifestyle variables, the PLS analysis was carried controlling for this variable. 324 
After a seven-fold cross-validation, three PLS factors were retained accounting for 325 
21.7% and 8.5% of the overall variability observed in predictor and response variables, 326 
respectively (Table 1). Lifestyle variables and clusters of NMR variables contributing highly 327 
to PLS factors were identified using factor loading values (Table 2). The first PLS factor was 328 
predominantly positively associated with dairy products and cakes and biscuits intake, while 329 
lifetime alcohol intake, smoking status and diabetes displayed negative loadings for this 330 
lifestyle component (Table 2). On the same PLS factor, signals mainly associated with 331 
glucose and bonds of lipids with negative loading values, and with aspartate, glutamine and 332 
lysine with positive loadings emerged on the metabolomic profile (Table 2). Lifestyle 333 
variables characterizing the second PLS factor included cereal products, height and education 334 
level with negative loadings, and hepatitis with positive loadings. The metabolic signature 335 
included NMR variables with positive loadings associated with aromatic amino acids 336 
(phenylalanine, tyrosine) and glucose; and those with negative loadings associated mainly 337 
with bonds of lipids, threonine and mannose (Table 2). The third PLS factor had a lifestyle 338 
pattern outlining intake of vegetables (high negative loadings values), lifetime alcohol 339 
consumption, smoking, and hepatitis infection (positive loadings). Its counterpart NMR 340 
pattern highlighted signals of glucose and aspartate, with high negative loadings, along with 341 
signals of ethanol, myo-inositol, proline and glutamate as prominent metabolites with positive 342 
loadings (Table 2). 343 
Conditional logistic regression models relating HCC risk with the X- and Y-scores are 344 
shown in Table 3. The first PLS factor was associated to a non-significant decreased HCC 345 
risk (23% and 4% in the X- and Y-scores respectively), while the second and third factors 346 
were associated to a statistically significant increased HCC risk (54% and 11%; and 37% and 347 
16 
 
22% respectively). Results for the ROC curves parameters are reported in Table 4, including 348 
AUC, sensitivity, specificity, accuracy and PPV for different combinations of the X- and Y-349 
scores. The AUC of the X-scores and Y-scores for all 3 PLS factors, adjusted for C-reactive 350 
protein concentration, alpha-fetoprotein concentration and the score of liver damage, was 351 
respectively 0.859 and 0.853. An increase in the resampled cross-validated AUC values was 352 
also observed for all three X- and Y-scores, albeit smaller, with respectively 0.836 and 0.827. 353 
Results from the sensitivity analysis conducted on data excluding sets where cases were 354 
diagnosed within the first two years of follow-up, showed similarities in terms of lifestyle 355 
variables’ and metabolites’ loadings on the PLS factors (Supplementary Table 2). Notable 356 
differences pertained to the identification of new signals for the first PLS factor including 357 
ethanol, histidine and an unknown compound. On the second lifestyle factor, BMI (positive 358 
loadings) replaced education level (negative loadings) while the reflected metabolomic profile 359 
was comparable to its counterpart from the main analysis (Supplementary Table 2). On the 360 
third factor, smoking status and hepatitis (positive loadings) were replaced by sugar and 361 
confectionary intake (negative loadings); signals contributing to the associated metabolic 362 
profile remained the same but the direction of the association was inversed as loadings had 363 
opposite signs as compared to the counterpart PLS factor of the main model (Supplementary 364 
Table 2). Corresponding ORs from conditional logistic regression models relating the X- and 365 
Y-scores to HCC risk are available in Table 5. The scores showed a statistically significant 366 
association in the second factor for both sets and in the third factor for the Y-set. ROC-367 
associated statistics for different models are presented in Supplementary Table 3. The VIP 368 
plot (Figure 3) displayed the results for the importance of the lifestyle variables in the 369 
prediction of the Y-set computed for the main PLS model performed including all subjects 370 
(panel A) and for the sensitivity model (panel B). The results suggested a potential gain in 371 
stability as prominent lifestyle variables for prediction were maintained 372 
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(hepatitis/diabetes/cakes and biscuits), the magnitude of the VIP was improved for some 373 
(fat/lifetime alcohol intake) and less emphasis was put on others (BMI/physical activity). 374 
Finally, the natural indirect effect was assessed in the mediation analyses and the results are 375 
presented in Table 6. Overall, there was limited evidence that metabolomic signals mediated 376 
the association between lifestyle components and HCC risk in the first PLS factor. Evidence 377 
of a significant mediated effect by the Y-scores was found in the second and third PLS factors 378 
when models were adjusted for exposure-mediator interaction (Table 6).  379 
Discussion 380 
In this work, an analytical strategy based on PLS analysis was conceived to extract 381 
relevant information from sets of lifestyle and NMR metabolomic variables, and to relate the 382 
resulting components to the risk of disease. This offered a way to implement the MITM 383 
approach [6] in a nested case-control study on HCC within the EPIC study. MITM has been 384 
suggested as a way to link specific putative metabolites to lifestyle exposures and disease 385 
outcomes, thus leading to the identification of potential intermediate biomarkers [6].  386 
An implementation of MITM was previously carried out in a nested case-control study 387 
in the Turin sub-cohort of EPIC [7] based on prospectively collected plasma samples from a 388 
pilot study on colon and breast cancers. In their work, a list of intermediate markers was 389 
identified by an in-parallel evaluation of the relationships between untargeted 1H NMR 390 
profiles with dietary exposures and risk of colon and breast cancers using correlation analysis 391 
and logistic regression. In our study, a different analytical framework was developed, largely 392 
exploiting features of PLS analysis, a multivariate technique that iteratively extracts 393 
components capturing co-variability in sets of predictors and response variables [8,40]. A set 394 
of lifestyle predictor variables were related to NMR responses. In a second step, PLS 395 
predictors’ and responses’ scores were linked to the risk of HCC.  396 
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Another sensitive issue in this analysis was the choice of lifestyle variables. Two 397 
disease-indicator variables reflecting environmental exposures, diabetes and hepatitis, were 398 
included in the set of predictors, as they turned out to have an important role in the 399 
characterization of metabolomic signatures. In addition, diabetes is the main metabolic risk 400 
factor for HCC alongside with fatty liver disease [41,42], and chronic infection with hepatitis 401 
B (HBV) and particularly hepatitis C (HCV) viruses were classified as class I carcinogens for 402 
HCC by IARC [43].  403 
Other relevant biomarkers were not part of the list of predictors in PLS analysis, but were 404 
controlled for in logistic regression models. This included C-reactive protein, alpha-405 
fetoprotein, and a score for liver damage,  an index of different circulating enzymes measured 406 
in the hepatic tissue indicating potential underlying liver function impairment [25]. The alpha-407 
fetoprotein was not included as an adjustment factor in the analyses not because of its 408 
established part as a serum marker for HCC diagnosis [26,44], but rather to account for it as a 409 
potential confounder that may cloud the relation between scores and HCC, both in conditional 410 
logistic regressions and in mediation analyses. 411 
Similarly to other multivariate techniques, a key aspect of PLS analysis is the choice 412 
of the number of factors to retain, in an effort of exhaustively summarizing data variability 413 
through a limited number of factors. Based on a seven-fold cross-validation, three linear 414 
combinations of variables were extracted in this work. A challenging aspect of this analysis is 415 
the interpretation of these factors, with respect to lifestyle and metabolomic variables. A 416 
subjective criterion based on the distribution of loading values was used throughout. The 417 
variables displaying the most extreme loading values (in absolute terms) were the ones 418 
characterizing each factor.  419 
The first lifestyle factor highlighted a healthy pattern with negative loadings for 420 
diabetes status, smoking status and lifetime alcohol intake, and was not associated to HCC 421 
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risk, similarly to its metabolomics counterpart. The lifestyle component of the second PLS 422 
factor, was reflective of a lifestyle pattern reflective of “higher-risk exposures”, and was 423 
related to a significant 54% increase in HCC risk. Likewise, its associated metabolic 424 
component displayed a significant HCC risk augmentation by 11%. The lifestyle component 425 
of the third PLS factor described participants with lower vegetables intake, elevated lifetime 426 
alcohol consumption, more likely to be ever smokers and hepatitis positive; one standard 427 
deviation increase of this component was associated to a statistically significant 37% increase 428 
in HCC risk. Similarly, a 22% significant increase in HCC risk was observed for its metabolic 429 
counterpart, characterized by positive signals of ethanol and myo-inositol, and displayed 430 
negative loadings for glucose.  431 
The MITM is captured by the rationale of PLS analysis, in the sense that each set of lifestyle 432 
profiles and metabolic signatures of the extracted PLS factors mirrored one another. In 433 
addition, mediation was observed for the second and third PLS factors, whereby the 434 
metabolomic component mediated the relation between the lifestyle component and HCC, for 435 
which statistically significant associations with HCC risk were estimated, emphasising the 436 
presence of a MITM. Mediation analysis relies on the assumption that there is no mediator-437 
outcome confounder that is affected by the exposure [35]. In our study C-reactive protein, 438 
alpha-fetoprotein and liver damage score were weakly correlated to lifestyle factor score, thus 439 
introducing potential bias in the estimation of direct and indirect effects in our mediation 440 
analysis. Additionally, a number of background confounders (mediator-outcome and 441 
exposure-outcome confounders) were present that we have tried to control for, either by 442 
adjustments or by accounting for potential interactions, however some degree of bias can 443 
remain and caution should be employed when interpreting the results. 444 
The predictive performance of PLS factors in relation to HCC occurrence was evaluated 445 
through an analysis of AUC values. The performance of the model was improved 446 
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progressively, with all 3 X- and Y-scores added; and reached an AUC of 0.859 with all 3 X-447 
scores and 0.853 with all 3 Y-scores, with adjustment for concentrations of C-reactive and 448 
alpha-fetoprotein, and for the liver damage score. Aafter a bootstrapped cross-validation, the 449 
AUC estimates were lower with respectively 0.836 and 0.827, but  the increase in the 450 
performance was nevertheless present. The ROC methodology allows estimation of PPV, 451 
which expresses the risk of disease after a positive test [45]. In a setting with low HCC 452 
prevalence (π=0.0004), in line with Western populations [46], extremely low PPV estimates 453 
were observed. In the absence of a very specific test, many positive tests arise from disease-454 
free individuals [45], thus leading to a dilution of PPV. 455 
A sensitivity analysis was carried out excluding the first two years of follow-up, but results 456 
were virtually unchanged, both in terms of relative risk estimates in logistic regression 457 
models, and of percentage of variability explained in PLS analysis. These findings suggest 458 
that reverse causation bias, if present, was minimal. 459 
This study had the ambition of integrating in the same analytical framework study 460 
participants’ lifestyle characteristics with a large number of NMR metabolic profiles. These 461 
data pose a number of methodological challenges due to their size and the complexity of 462 
exhaustively capturing and interpreting the biological processes they reflect. To address these 463 
issues, techniques involving multivariate statistics have been progressively revived in the 464 
recent years [2]. Epidemiologic evaluations of metabolomic data frequently combined PLS 465 
with discriminant analysis, such as PLS-DA or O-PLS-DA. The main objective of these 466 
methods is to identify a series of metabolomic features distinguishing between two very 467 
distinct groups of study participants [47,48]. In such strategies, only one set of variables is 468 
multi-dimensional and the response is one variable only. Similar multivariate techniques for 469 
pattern extraction, belonging to the family of regression methods, include reduced rank 470 
regression. This multivariate method relates an ensemble of response variables to a set of 471 
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predictor variables where the estimated matrix of the regression coefficients is of reduced 472 
rank [49–51]. In addition, canonical correlation analysis (CCA) [52] is a method applied to 473 
identify the optimum structure or dimensionality of each variable set that maximizes the 474 
relationship between two sets of multi-dimensional variables. The main difference between 475 
CCA and PLS regression is that CCA maximizes the correlation between the two new 476 
dimensions, i.e. extracted factors, whereas PLS maximizes their covariance. PLS can be 477 
considered as a trade-off  between CCA and PCA, since maximizing the covariance 478 
corresponds to maximizing the product of the correlation and standard deviation, given that 479 
cov(X,Y)=cor(X,Y)*SD(X)*SD(Y). 480 
Untargeted NMR was used in this work to acquire metabolomic signals. Prior to PLS 481 
analysis, a bucketing procedure, the statistical recoupling of variables (SRV) [17,53], was 482 
applied to reduce the number of NMR variables to 285 clusters. This was done by aggregating 483 
consecutive NMR bins based on their covariance to correlation ratio. , thus reconstructing 484 
peak entities. Neighbouring variables were then merged into clusters, to recover NMR 485 
multiplets, corresponding to NMR variables of interest. This alloweds the identification of 486 
informative components of the spectra, thus acting as an efficient noise-removing filter. 487 
Subsequently the annotation effort remains challenging, for a number of reasons. The 488 
majority of published metabolomics studies often identified a limited number of metabolites 489 
at a time [54], and the Human Metabolome Database (HMDB) and other related resources 490 
[18,55], that offer richly annotated information continuously increasing the metabolite 491 
coverage for users, are mostly exploited through time consuming interactive procedures. In 492 
addition, individual metabolites often overlap in NMR signals, which can hinder 493 
interpretation of the annotated metabolic profilesannotations. Untargeted NMR approaches 494 
are useful for the identification of metabolites of moderate abundance; however they may 495 
miss low-abundance metabolites due to the intrinsically low NMR sensitivity. These 496 
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challenges, as well as large variability in metabolite concentrations, and disentangling 497 
informative signals from noise, are not specific to NMR and pertain to any type of untargeted 498 
technique. Such investigations may profit from complementary targeted metabolomic 499 
analytical strategies [55].  500 
Throughout the different steps of this work, the scaling problem was first tackled by 501 
normalizing spectra to total intensity. NMR data were also centered and Pareto-scaled, 502 
together with correction for potential batch effects [16]. The PC-PR2 method offered a way to 503 
investigate major sources of systematic variability in NMR and lifestyle data [15]. The 504 
variable “country of origin” emerged as the variable accounting for the largest proportion of 505 
total variability, and the residual method was used to control for this variable in the following 506 
steps of the analysis. While this may lead to removing regional gradients of dietary 507 
variability, this step is instrumental to avoid unwanted systematic regional-specific bias in the 508 
data in country-specific questionnaire assessments. In addition, technical aspects like storage 509 
and handling of biological samples, fasting status at blood collection are specific to each 510 
country [15]. In any case, variability due to “country of origin” is not exploited in conditional 511 
logistic models, as cases and controls were also matched on center. 512 
One of the limitations of this study is the restricted sample size which raises concerns 513 
with regards to power to detect associations. While a larger sample size would possibly result 514 
in more statistically significant findings, we used the data that was available with NMR 515 
profiles measured. In this work we have developed a framework to analyse complex data 516 
integrating lifestyle and metabolomics in relation to risk of disease. The approach described in 517 
this study has merits but also pitfalls among which it is worth mentioning that statistical 518 
methods are used repeatedly on the same set of data, notably the PLS model, the conditional 519 
logistic regression, the AUC estimation and mediation analysis. To partially address this, a 520 
cross-validation approach was devised for AUC estimation which involved conditional 521 
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logistic regression, whereby PLS was done without knowledge of the case/control status. 522 
However, conditional logistic regression models and mediation analyses were implemented 523 
on the same data, and our analysis did not account for this limitation. This may have led to 524 
spuriously increase the nominal level of statistical significance of statistical tests.  525 
Conclusion 526 
The MITM emerged as a method for the identification of relevant biomarkers, with 527 
great potential to unravel utmost important steps in the aetiology of disease. The analytical 528 
strategy for MITM was developed to use all potentially informative aspects of high-529 
throughput data by integrating metabolomic, dietary and lifestyle exposures together with 530 
disease indicators. While the framework was applied towards the investigation of HCC 531 
determinants, it can be easily extended to similar aetiological contexts and applied to other –532 
omics settings. 533 
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Legends to figures  758 
Figure 1: General scheme of the analytical framework developed in the study. A PC-PR2 759 
analysis is carried out beforehand to identify relevant sources of variation. In the PLS model 760 
the X- and Y- sets are related to each other, and scores are computed (1). X- and Y-scores are, 761 
in turn, associated to a case-control indicator of HCC status in conditional logistic regression 762 
models (2). A mediation analysis is carried out to explore the role of metabolomics in the 763 
association between lifestyle factors and risk of HCC (3). 764 
Figure 2: PC-PR2 analysis results* identifying the sources of variability in the NMR data 765 
(panel A) and in the lifestyle data (panel B). 766 
* 17 and 14 components were retained to account for 80 % (threshold used) of total NMR (A) 767 
and lifestyle variability (B), respectively. The R2 value represents the amount of variability in 768 
NMR / lifestyle variable explained by the ensemble of investigated predictors. 769 
Figure 3: Variable importance plot (VIP) displaying the variable importance for projection 770 
statistic of the predictor variables for the PLS analyses. 771 
Panel A: Results from the main PLS model run on all observations (N=336, X-set=21, Y-772 
set=285). 773 
Panel B: Results from the PLS sensitivity analysis run on a subsample (N=271, 92 cases, 179 774 
controls) excluding sets where cases were diagnosed within the first two years of follow-up 775 
(X-set=21, Y-set=285). 776 
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The horizontal line corresponds to Wold’s criterion (0.8), the threshold used to rule if a 777 
variable has an important contribution to the construction of the Y variables (see 778 
Mathematical Appendix for further details). 779 
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Table 1: Individual and cumulative variation (%) explained by the first 3 PLS factors in 21 lifestyle (X-set) and 285 
NMR (Y-set) variables. 
# of 
PLS  Lifestyle Variables NMR Variables 
Factors Individual  Cumulative  Individual Cumulative  
1 6.17 - 5.51 - 
2 6.23 12.40 2.38 7.89 
3 9.27 21.67 0.59 8.48 
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Table 2: Lifestyle and NMR cluster variables contributing to each of the 3 PLS factors (N=336, X-set=21, Y-
set=285). 
PLS 
Factor Lifestyle Variable* 
Loading 
value 
CS*‡ 
(ppm) Metabolite** 
Loading 
value 
1 Dairy Products 0.28 5.22 
Glucose 
-0.06 
  Cakes and Biscuits 0.32 3.88 -0.05 
  Lifetime Alcohol Consumption -0.25 3.82 -0.06 
  Smoking Status -0.39 3.76 -0.06 
  Diabetes -0.63 3.71 -0.05 
    3.54 -0.05 
    3.50 -0.07 
    3.48 -0.07 
    3.44 Acetoacetate -0.07 
    3.23 Choline + Glycerphosphocholine  -0.04 
    3.01 Lysine 0.10 
    2.94 Albumin 0.10 
    2.65 Aspartate 0.10 
    2.42 Glutamine 0.10 
    2.28 Acetoacetate 0.10 
    2.22 CH2-CH2-COOC bond of lipids + Acetone -0.04 
    1.86 Lysine 0.09     1.87 0.10 
      1.53 CH2-CH2-COOC bond of lipids  -0.03 
2 Cereal and Cereal Products -0.16 7.17 Tyrosine 0.13   Height -0.34 6.87 0.13 
  Education Level -0.26 5.27 CH=CH bond of lipids -0.13 
  Hepatitis 0.49 5.22 Glucose 0.16 
    5.18 Mannose + Lipid O-CH2 -0.12
    4.27 Lipid O-CH2 -0.12 
    4.25 Threonine -0.14
    4.07 Choline + Lipid O-CH2 + Myo-inositol -0.12 
    4.05 Creatinine -0.14
    3.88 
Glucose 
0.15 
    3.82 0.16 
    3.76 0.15 
    3.71 0.15 
    3.54 0.15 
    3.50 0.16 
    3.48 0.16
    3.44 Acetoacetate 0.16 
    3.23 Choline + Glycerphosphocholine 0.15
    2.80 Aspartate -0.12 
    2.22 CH2-CH2-COOC bond of lipids + Acetone -0.11
    2.19 CH2-CH2-COOC bond of lipids -0.15
    2.02 Proline  + Glutamate + CH2=C bonds of lipids -0.13 
    1.53 CH2-CH2-COOC bond of lipids -0.13
    1.25 CH2 bond of lipids  -0.12 
      0.86 Cholesterol + CH3 bond of lipids -0.12
3 Vegetables -0.42 7.32 Phenylalanine 0.11 
  Lifetime Alcohol Consumption 0.29 5.22 Glucose -0.13
  Smoking Status 0.25 4.28 Lipid O-CH2  0.11 
  Hepatitis 0.26 3.88 
Glucose 
-0.11 
    3.82 -0.11 
    3.76 -0.12 
    3.71 -0.11 
    3.69 -0.11 
    3.63 Myo-inositol 0.16
    3.50 Glucose -0.13     3.48 -0.12 
    3.44 Acetoacetate -0.12 
    3.35 Proline 0.11     3.33 0.13 
    3.28 Myo-inositol 0.12 
    3.23 Choline + Glycerphosphocholine  -0.12 
    2.80 Aspartate -0.13 
    2.76 part of =CH-CH2-CH= bond of lipids  -0.13 
    2.35 Proline + Glutamate 0.12     2.33 0.13
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    1.20 3-hydroxybutyrate + CH2 bond of lipids  0.11 
    1.16 Ethanol 0.15 
      0.66 Cholesterol 0.11 
*Relevant lifestyle and NMR variables contributing to each PLS factor selected based on their associated loading 
values <10th percentile (pctl) and >90th pctl or <5th pctl and >95th pctl respectively. 
‡ CS: 1H chemical shift (in ppm) of the cluster (center value). 
**Some of the identified clusters were found to be background noise during the annotation phase and were removed 
from this table. 
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Table 3: HCC odds ratios* and 95% confidence interval (OR, 95% CI) associated with the lifestyle (X-set) and the 
NMR clusters (Y-set) PLS scores in the main analysis (N=336, X-set=21, Y-set=285). 
 
PLS Lifestyle Variables 
X-scores 
PLS NMR Variables 
Y-scores 
Factor OR** (95% CI) P-Wald† Factor OR** (95% CI) P-Wald† 
1 0.77 (0.58, 1.02)  0.07 1 0.96 (0.91, 1.01) 0.09 
2 1.54 (1.06, 2.25) 0.02 2 1.11 (1.02, 1.22) 0.02 
3 1.37 (1.05, 1.79) 0.02 3 1.22 (1.04, 1.44) 0.01 
*Models were adjusted for C-reactive protein concentration, alpha-fetoprotein concentration and a composite score for 
liver damage. Cases and controls were matched on age at blood collection (± 1 year), sex, study centre, date (± 2 
months) and time of the day at blood collection (± 3 hours), fasting status at blood collection (<3/3-6/>6 hours); 
among women, additional matching criteria included menopausal status (pre-/peri-/postmenopausal) and hormone 
replacement therapy use at time of blood collection (yes/no). ** ORs expressing the change in HCC risk associated to 
1-SD increase in the score. † Wald's test was for continuous exposure compared with a Chi-square distribution with 1 
degree of freedom (dof). 
 
 
 
Table 4: Area under the curve (AUC), sensitivity, specificity, accuracy and positive predictive value (PPV) of ROC 
models (with 95% CI), from the main PLS analysis (N=336, X-set=21, Y-set=285). 
 
AUC AUCb** Sensitivity Specificity Accuracy PPV 
Adjustment Covariates (ADJ)* 0.842 (0.794, 0.891) 0.821 (0.766, 0.868) 0.752 (0.662, 0.829) 0.802 (0.743, 0.852) 0.785 0.0015
 
X1 scores + ADJ 0.846 (0.797, 0.894) 0.825 (0.766, 0.875) 0.743 (0.653, 0.821) 0.838 (0.783, 0.884) 0.806 0.0018 
X1+X2 scores + ADJ 0.854 (0.808, 0.900) 0.831 (0.772, 0.881) 0.743 (0.653, 0.821) 0.824 (0.768, 0.872) 0.797 0.0017 
X1+X2+X3 scores + ADJ 0.859 (0.811, 0.907) 0.836 (0.778, 0.887) 0.796 (0.710, 0.866) 0.788 (0.729, 0.840) 0.791 0.0015 
 
Y1 scores + ADJ 0.841 (0.793, 0.890) 0.817 (0.760, 0.865) 0.735 (0.643, 0.813) 0.820 (0.763, 0.868) 0.791 0.0016 
Y1+Y2 scores + ADJ 0.845 (0.795, 0.894) 0.820 (0.762, 0.872) 0.735 (0.643, 0.813) 0.851 (0.798, 0.895) 0.812 0.0020
Y1+Y2+Y3 scores + ADJ 0.853 (0.804, 0.902) 0.827 (0.771, 0.877) 0.726 (0.634, 0.805) 0.883 (0.833, 0.922) 0.890 0.0025 
*The model is run on the adjustment covariates (ADJ) including the C-reactive protein concentration, alpha-
fetoprotein concentration and a composite score for liver damage. ** AUCb is the bootstrapped-cross validated 
estimate of the AUC. X1, X2 and X3 are the lifestyle component scores of the first, second and third PLS factors, 
respectively. Y1, Y2, and Y3 are the metabolomics component of the first, second and third PLS factors, respectively. 
 
 
Table 5: HCC odds ratios* and 95% confidence intervals (OR, 95%CI) associated with the lifestyle (X-set) and the 
NMR clusters (Y-set) PLS scores. Results from the sensitivity analysis (N=271, 92 cases, 179 controls) conducted 
excluding sets where cases were diagnosed within the first two years of follow-up (X-set=21, Y-set=285). 
 
PLS Lifestyle Variables 
X-scores 
PLS NMR Variables 
Y-scores 
Factor OR** (95% CI) P-Wald† Factor OR** (95% CI) P-Wald† 
1 0.80 (0.60, 1.08) 0.15 1 0.96 (0.94, 1.04) 0.56 
2 1.56 (1.02, 2.40) 0.04 2 1.18 (1.03, 1.36) 0.02 
3 0.86 (0.67, 1.11) 0.26 3 0.86 (0.73, 0.99) <0.05 
*Models were adjusted for C-reactive protein concentration, alpha-fetoprotein concentration and a composite score for 
liver damage. Cases and controls were matched on age at blood collection (± 1 year), sex, study centre, date (± 2 
months) and time of the day at blood collection (± 3 hours), fasting status at blood collection (<3/3-6/>6 hours); 
among women, additional matching criteria included menopausal status (pre-/peri-/postmenopausal) and hormone 
replacement therapy use at time of blood collection (yes/no). ** ORs expressing the change in HCC risk associated to 
1-SD increase in the score. † Wald's test was for continuous exposure compared with a Chi-square distribution with 1 
degree of freedom (dof). 
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Table 6: Results from the mediation analysis (N= 336, X-set=21, Y-set=285): Natural Indirect Effect 
(NIE) and 95%CI*. 
 
Model**  Natural Indirect Effect (NIE) 
Exposure 
(A) Mediator (M) Outcome 
A*M 
interaction 
term 
Estimate (95%CI) p-value 
X1 score Y1 score HCC No 0.91 (0.77, 1.06) 0.23 
X2 score Y2 score HCC No 1.11 (0.97, 1.25) 0.12 
X3 score Y3 score HCC No 1.08 (0.94, 1.23) 0.28 
X1 score Y1 score HCC Yes 0.96 (0.79, 1.17) 0.70 
X2 score Y2 score HCC Yes 1.15 (1.01, 1.31) 0.04
X3 score Y3 score HCC Yes 1.13 (1.01, 1.28) 0.04 
* The standard errors used to compute the 95%CI were obtained using the delta method. 
**Models were adjusted for the C-reactive protein concentration, alpha-fetoprotein concentration and 
a composite score for liver damage, as well as for the other Y-scores, as potential mediator-outcome 
confounders. Additionally, the outcome and the mediator models were adjusted for centre and age at 
blood collection. 
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A statistical framework to model the
meeting-in-the-middle principle using metabolomic data:
application to hepatocellular carcinoma in the EPIC
study.
1 PLS regression
1.1 Introduction
PLS (partial least squares) regression is a widely used method in multivariate statistics to relate
two sets of variables while reducing their dimensionality. It was ﬁrst developed as a method
to predict a set of variables Y from another set X; and also to depict their common structure.
The main aim of PLS is to regress a set Y of q variables (y1, y2, . . . , yq) of interest, which
are called responses, on a set X of p predictor variables (x1, x2, . . . , xp) that may display high
levels of correlation. PLS combines and generalizes features of principal component analysis
(PCA) and multiple linear regression (MLR); and results in a set of PLS latent factors as linear
combinations of variables, in turn, in the X- and Y -sets. By simultaneously decomposing X
and Y , PLS ﬁnds components that explain as much as possible of the inter-relations of X and
Y . The latent factors obtained from the decomposition can be used to predict Y . The following
details of the algorithm are adapted from Michel Tenenhaus' book La régression PLS, Théorie
et Pratique [1].
1
1.2 The PLS algorithm
Two diﬀerent, but closely related, techniques exist under the name of PLS regression. The
canonical or symmetric PLS regression assumes that the X- and Y - sets play a symmetrical
role. The version presented here is the regression mode where latent variables are computed
from a succession of singular value decompositions (SVD) followed by deﬂation of both the
X- and Y - matrices. These sets are assumed to play the asymmetric roles of predictors and
responses, respectively. Next, we brieﬂy describe the landmark algorithm NIPALS Nonlinear
estimation by Iterative Partial Least Squares. As a ﬁrst step, two substitute matrices X0 and
Y0 are initialized with X0 = X(n×p) and Y0 = Y(n×q), where variables were standardized to have
means and standard deviations equal to zero and one, respectively. For h = 1, . . . , H, where
H = min(p, q), the PLS factors are obtained iteratively. PLS regression focuses on ﬁnding two
sets of weights, wh(p×1) and ch(q×1), in order to create respectively a linear combination of the
columns of X and Y , known as the PLS factors, such that these two linear combinations have
maximum covariance and are unique. These weights deﬁne a ﬁrst pair of vectors, called the X-
and Y -scores, th = Xwh and uh = Y ch where we have t
ᵀ
huh maximal. PLS can be written as
the following optimisation problem where maximum covariance is sought between th(1×n) and
uh(1×n) for each h = 1 · · ·H:
Max cov(Xwh, Y ch) (1)
under the following normality constraints
‖wh‖ = 1 (2)
‖ch‖ = 1 (3)
and the following orthogonality constraint
tᵀh(t1, . . . , th−1) = 0 (4)
By construction we also have the following property:
uᵀh(t1, . . . , th−1) = 0 (5)
The ﬁrst pair of X- and Y - scores can equivalently be obtained via a singular value decom-
position. Indeed, the SVD of the cross-product matrix Xᵀh−1Yh−1 leads to the identiﬁcation of
the ﬁrst left and right singular vectors and of the weights wh and ch. The scores th and uh are
obtained as follows:
th = Xh−1wh (6)
uh = Yh−1ch (7)
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The vector th is then normalized (a scaling of uh is optional). Regressing the predictor and
response matrices on the th vector yields the corresponding loadings.
ph = X
ᵀ
h−1th (8)
ch = Y
ᵀ
h−1th (9)
Next is the deﬂation step, where information based on the extracted latent factor h is subtracted
from the current data matrices.
Xh = Xh−1 − thpᵀh (10)
Yh = Yh−1 − thcᵀh (11)
The described steps of the algorithm are iterated until one of the following criteria is met:
 If H is speciﬁed, and the algorithm stops when the H-th PLS factor is extracted and its
associated statistics computed.
 If H is not speciﬁed, the algorithm stops when XH becomes a null matrix. In this case
however, H cannot exceed min(p, q).
Algorithm 1 PLS1 classic algorithm steps - When Y is univariate.
1: X0 ← X ; y0 ← y
2: for (h = 1;h ≤ H;h + +) do
3: wh = X
ᵀ
h−1yh−1/yᵀh−1yh−1
4: wh = wh/
√
wᵀhwh
5: th = Xh−1wh/wᵀhwh
6: ph = X
ᵀ
h−1th/tᵀhth
7: Xh = Xh−1 − thpᵀh
8: ch = y
ᵀ
h−1th/tᵀhth
9: uh = yh−1/ch
10: yh = yh−1 − chth
When Y is univariate, the PLS algorithm carried out is PLS1 (See Algorithm 1, following
the notation of M. Tenenhaus [1]). PLS2 (Algorithm 2) is used when Y is multivariate. When
there are missing data in either the X- or Y - sets, the coordinates of the vectors wh, th, ch, uh,
and ph are computed as slopes of the least squares straight line that passes through the origin,
using the available data as follows:
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Algorithm 2 PLS2 classic algorithm steps - When Y is multivariate.
1: X0 ← X ; Y0 ← Y
2: for (h = 1;h ≤ H;h + +) do
3: uh = Yh−1[, 1] i.e. the ﬁrst column of the matrix
4: while wh has not converged do
5: wh = X
ᵀ
h−1uh/uᵀhuh
6: wh = wh/
√
wᵀhwh
7: th = Xh−1wh/wᵀhwh
8: ch = Y
ᵀ
h−1th/tᵀhth
9: uh = Yh−1ch/cᵀhch
10: ph = X
ᵀ
h−1th/tᵀhth
11: Xh = Xh−1 − thpᵀh
12: Yh = Yh−1 − thcᵀh
 wh = (wh1, . . . , whp)
ᵀ, is a normalized vector, where whj is the slope of the least squares
line passing through the origin of the plane deﬁned by (uh, Xh−1,j). Xh−1,j is the j-th X
variable of the h− 1 PLS factor.
 th = (th1, . . . , thn)
ᵀ, where thi is the slope of the least squares line passing through the
origin of the plane deﬁned by (wh, xh−1,i). xh−1,i is the i-th x observation of the h − 1
PLS factor.
 ch = (ch1, . . . , chq)
ᵀ, where chk is the slope of the least squares line passing through the
origin of the plane deﬁned by (th, Yh−1,k). Yh−1,k is the k-th Y variable of the h− 1 PLS
factor.
 uh = (uh1, . . . , uhn)
ᵀ, where uhi is the slope of the least squares line passing through the
origin of the plane deﬁned by (ch, yh−1,i). yh−1,i is the i-th y observation of the h− 1 PLS
factor.
 ph = (ph1, . . . , php)
ᵀ, where phj is the slope of the least squares line passing through the
origin of the plane deﬁned by (th, Xh−1,j). Xh−1,j is the j-th X variable of the h− 1 PLS
factor.
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1.3 Tools for interpretation
1.3.1 Choice of number of components
The number of PLS latent factors or components to be retained can be decided based on a
cross-validation.
For each model with a number h of extracted factors, this is done by running the PLS analysis
on only a part of the data called the training set, and then evaluating how well the model
ﬁts observations in the test set. This includes the part of the data not involved in the PLS
modelling of the training set.
The dataset comprised of n observations is split into z approximately equal sets of observations.
The training set consists of the data in the ﬁrst z − 1 folds and the remaining fold is used as
test set. Predicted values for the Y -set are computed on this test set along with the sum of the
squared error of prediction. This process is repeated z times so that each fold can in turn serve
as a test set. In practice, for each number of possible latent factors h = 1, . . . , H, we compute
the prediction of yi by the PLS model with results obtained on the training set with a number
h of components applied to observations in the test set in order to yield yˆh(−i). The Prediction
Error Sum of Squares (PRESS) is the resulting sum of all squared errors of prediction statistic
computed across all test sets as deﬁned in the following equation:
PRESSh =
∑
(yi − yˆh(−i))2 (12)
The Residual Sum of Squares (RSS) is computed in a standard way:
RSSh =
∑
(yi − yˆhi)2 (13)
Diﬀerent criteria can be used to determine the number of components h to retain. One such
criterion, Q2h was ﬁrst introduced by H. Wold [2] and is mainly used in the software SIMCA-P.
It is based on the following statistic:
Q2h = 1−
PRESSh
RSSh−1
(14)
As pointed out by M. Tenenhaus, the initial value for RSS when y is univariate centred-scaled
and h = 0 is:
RSS0 =
n∑
i=1
(yi − y¯)2 = n− 1 (15)
In the software SIMCA-P the PLS component is kept when the following condition is met:√
PRESSh ≤ 0.95
√
RSSh−1 (16)
⇐⇒ Q2h > 0.0975 (17)
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The default threshold 0.0975 is equal to 1− 0.952. In SAS, the criteria to select the number h
of components to be retained is by minimizing the PRESSh statistic.
The above described formulae can be generalized for multivariate Y , thus we have for any given
variable yk, k = 1, . . . , q:
Q2kh = 1−
PRESSkh
RSSk(h−1)
(18)
Q2h = 1−
∑q
k=1 PRESSkh∑q
k=1RSSk(h−1)
(19)
The criteria for keeping a PLS factor are identical to what was established for the univariate
case. One can alternately use one of the following rules, where the equivalence deﬁned in
formula (17) still holds true:
 Q2h > 0.0975
 At least one value of Q2hk > 0.0975
If the criteria are met by several values of h, the one retained is the smallest h, to achieve a
better dimensionality reduction.
The Q2 and PRESS criteria are relatively robust to the choice of number of folds (blocks) used
for cross-validation. A number of folds between 5 and 10 is recommended (Tenenhaus 1998,
p.238) [1]. The default choice in the SIMCA-P and SAS softwares is 7, and is the parameter
used in this study.
1.3.2 Variable Importance in the Projection (VIP)
The Variable Importance in the Projection (VIP) is a measure of the explanatory power of a
given variable xj over Y . The V IPhj of a given component h of the j-th variable xj is deﬁned
as:
V IPhj =
√√√√ p
Rd(Y ; t1, . . . , th)
h∑
l=1
Rd(Y, tl)w2lj (20)
and one has:
p∑
j=1
V IP 2hj = p (21)
where Rd(Y ; t1, . . . , th) is the redundancy of Y with respect to the t scores (t1, . . . , th). It
describes the amount of variance of Y explained by the component th of the X-set. It is deﬁned
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as follows:
Rd(Y, th) =
1
q
q∑
k=1
cor2(yk, th) (22)
It can be equivalently computed as:
Rd(Y, th) = r
2
h
1
q
q∑
k=1
cor2(yk, uh) (23)
where rh = cor(Xwh, Y ch) is called a canonical correlation and r
2
h is the h
th largest eigenvalue
of the crossproduct matrix decomposition.
The contribution of a variable xj to the construction of a component tl is measured by the
weight w2lj. For each l, with l = 1, . . . , h, the sum of these weights across the p variables xj
equals 1. To measure the contribution of the variable xj to the construction of Y through
the components tl, one should consider the explanatory power of the component tl, measured
by the redundancy Rd(Y ; tl). An equal weight w
2
lj indicates an explanatory power of the xj
variable over the Y -set whose importance increases with the level of redundancy Rd(Y ; tl).
The VIP enables the ranking of the predictors xj according to their explanatory power on Y ,
and summarizes their contribution to the model. A VIP is considered small if its value is less
than 0.8 and high when its value is greater than 1. Variables with a high VIP (V IP > 1) are
the most important for the reconstruction and prediction of Y .
2 Statistical Recoupling of Variables (SRV)
The SRV procedure was introduced by Blaise et al.(2009) [3] and for which a matlab toolbox was
later implemented [4]. The SRV is an "intelligent bucketing" algorithm that aims at regrouping
variables (typically the smallest unit of the NMR spectrum) in clusters corresponding to a wider
biological and chemical entity.
SRV exploits the spectral structure of data, without forming any metabolic hypothesis to reduce
the dimensionality of spectra. A typical NMR 1H 9 ppm spectrum is often partitioned into
9, 000 buckets of 0.001 ppm width. The main idea of the algorithm is to exploit the spectral
dependency landscape L which is the covariance to correlation ratio between two neighbouring
variables along the chemical shift axis to assemble them within a cluster. If one considers a
matrix Z of serum spectra acquired by NMR with n observations and r columns (z1, . . . , zr)
corresponding to neighbouring bins of NMR signals. The ﬁrst bin-variable starts the ﬁrst
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cluster, then L is computed for each zi as follows with i = 1, . . . , r :
L(zi) =
cov(zi, zi+1)
cor(zi, zi+1)
(24)
= sd(zi) ∗ sd(zi+1)
where sd is the standard deviation.
The variable then joins a cluster according to the following rules:
 L(zi) values are used to locate local minima i.e. borders between clusters.
 If L(zi−1) > L(zi) then zi−1 and zi are associated in the same cluster, otherwise zi and
zi+1 start a new cluster.
 The minimum number of variables belonging to a cluster is set a priori as it is based on
the resolution of the NMR spectra. When acquired at 700 MHz, the typical peak base
width of a well-resolved singlet is equal to 7 Hz. Therefore, the threshold was set to 10
in our analysis, meaning that if a cluster has less than 10 variables, it is discarded.
 The super-cluster intensity is computed as the mean of the intensities of the signal in the
bins assigned to the super-cluster.
 If two neighbouring clusters have a correlation > 0.9, they are aggregated to form a
super-cluster. In these analyses, the association is limited to 3 clusters per super-cluster
(this value is empirical and was discussed in the original paper [3]).
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Abstract 48 
Metabolomics is a potentially powerful tool for identification of biomarkers associated with 49 
lifestyle exposures and risk of various diseases. This is the rationale of the “meeting-in-the-50 
middle” concept, for which an analytical framework was developed in this study. In a nested 51 
case-control study on hepatocellular carcinoma (HCC) within the European Prospective 52 
Investigation into Cancer and nutrition (EPIC), serum 1H NMR spectra (800 MHz) were 53 
acquired for 114 cases and 222 matched controls. Through Partial Least Square (PLS) 54 
analysis, 21 lifestyle variables (the “predictors”, including information on diet, anthropometry 55 
and clinical characteristics) were linked to a set of 285 metabolic variables (the “responses”). 56 
The three resulting scores were related to HCC risk by means of conditional logistic 57 
regressions. The first PLS factor was not associated with HCC risk. The second PLS 58 
metabolomic factor was positively associated with tyrosine and glucose, and was related to a 59 
significantly increased HCC risk with OR= 1.11 (95%CI: 1.02, 1.22, p=0.02) for a 1-SD 60 
change in the responses score, and a similar association was found for the corresponding 61 
lifestyle component of the factor. The third PLS lifestyle factor was associated with lifetime 62 
alcohol consumption, hepatitis and smoking, and had negative loadings on vegetables intake. 63 
Its metabolomic counterpart displayed positive loadings on ethanol, glutamate and 64 
phenylalanine. These factors were positively and statistically significantly associated with 65 
HCC risk, with 1.37 (1.05, 1.79, p=0.02) and 1.22 (1.04, 1.44, p=0.01), respectively. Evidence 66 
of mediation was found in both the second and third PLS factors, where the metabolomic 67 
signals mediated the relation between the lifestyle component and HCC outcome. This study 68 
devised a way to bridge lifestyle variables to HCC risk through NMR metabolomics data. 69 
This implementation of the “meeting-in-the-middle” approach finds natural applications in 70 
settings characterized by high-dimensional data, increasingly frequent in the –omics 71 
generation. 72 
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Introduction 75 
Metabolomic profiles from blood and other biological samples collected from large-76 
scale epidemiologic studies are increasingly being investigated [1], following recent 77 
developments in nuclear magnetic resonance (NMR) and mass spectrometry (MS) enabling 78 
the assessment of metabolic profiles for large numbers of individuals. As a result, 79 
metabolomic data is gradually playing a key part in clinical and observational studies; and 80 
new statistical methodologies [2] are increasingly being sought to explore insights into 81 
pathological processes that metabolomics may provide in order to better understand 82 
determinants of disease development. These approaches explore a variety of etiological 83 
hypotheses; however they usually focus on one aspect at a time, combining metabolomics 84 
with either epidemiologic/phenotypic data on lifestyle exposures [3] or with disease outcomes 85 
[4,5]. The main aim of this work is to jointly use all aspects that are potentially informative to 86 
apprehend the contrivances of disease development.  87 
Metabolomic data offers the opportunity to identify signatures and biomarkers 88 
associated with environmental exposures and the risk of a disease. Prospective studies are 89 
conceptually suitable for this purpose, since they rely on biological samples collected before 90 
disease onset, and are thus marginally influenced by metabolic changes due to processes of 91 
disease development. In this scenario, the “meeting-in-the-middle” (MITM) approach [6] has 92 
been conceived as a research strategy to identify biomarkers that are related to specific 93 
exposures and that are, at the same time, predictive of disease outcome. Finding this overlap 94 
between exposure and disease of “intermediate” biomarkers can potentially disclose useful 95 
information on the exposure-to-disease pathway, and may serve as an objective risk exposure 96 
measure, ultimately allowing the identification of a targeted prevention scheme. The MITM 97 
was previously implemented as a proof of concept in a case-control study nested within a 98 
cohort of healthy individuals [7], where a list of putative intermediate 1H NMR biomarkers 99 
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linking exposure to dietary compounds, mainly micro- and macronutrients, and disease 100 
outcomes (colon and breast cancer) were investigated.  101 
In this study we extend previous attempts to model the MITM by fully integrating 102 
metabolomics, lifestyle and disease risk in a single analytical framework. A strategy was 103 
developed to simultaneously investigate a broad range of metabolites and lifestyle variables 104 
with a partial least square (PLS) regression model [8]. The resulting scores were related to the 105 
risk of hepatocellular carcinoma (HCC), in a case-control study nested within the European 106 
Prospective Investigation into Cancer and nutrition (EPIC). HCC is the most frequent primary 107 
form of cancer affecting the liver, an organ that plays a critical role in many metabolic 108 
pathways [9]. HCC is a disease with multifactorial origins embracing lifestyle and dietary 109 
exposures whose intersection may reveal metabolomic signals [10] relevant to cancer onset. 110 
The system of relationships between metabolomic profiles and lifestyle factors in relation to 111 
HCC was evaluated by means of mediation analysis. The methodological challenges 112 
characterizing the analysis of large and complex metabolomic datasets are described and 113 
discussed. 114 
Methods 115 
EPIC design. The European Prospective Investigation into Cancer and nutrition (EPIC) is a 116 
large cohort established to investigate the association of diet, lifestyle and environmental 117 
factors with cancer incidence and other chronic disease outcomes. Between 1992-2000, over 118 
520,000 participants aged 20-85 years, were recruited from 23 centers in 10 Western 119 
European countries including Denmark, France, Germany, Greece, Italy, Norway, Spain, 120 
Sweden, The Netherlands and the United Kingdom [11].  The design, rationale and methods 121 
of the EPIC study including information on dietary assessment methodology, blood collection 122 
protocols and follow-up procedures were previously detailed [11].   123 
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Between 1992 and 1998, standardized lifestyle data, anthropometric measures and biological 124 
samples were collected at recruitment, prior to onset of any disease [11]. Validated country-125 
specific questionnaires ensuring high compliance were used to measure diet over the previous 126 
12 months [12]. Blood samples are stored at the International Agency for Research on Cancer 127 
(IARC, Lyon, France) in -196˚C liquid nitrogen for all countries, exceptions being Denmark 128 
(nitrogen vapour,-150˚C) and Sweden (freezers, -80˚C).  129 
The nested case-control study. The present study focused on data with available sera samples 130 
from a nested case-control study in EPIC on hepatocellular carcinoma (HCC) [13]. Cases of 131 
HCC were identified from all participating EPIC centres except for Norway and France 132 
(n=117) from recruitment (1993-1998) up to 2007. Two controls (n=232) were selected for 133 
each case from all cohort members alive and free of cancer (except non-melanoma skin 134 
cancer) by incidence-density sampling and were matched on age at blood collection (±1 year), 135 
sex, study centre, date (±2 months), time of the day at blood collection (±3 hours) and fasting 136 
status at blood collection (<3, 3-6, >6 hours); among women, additional matching criteria 137 
included menopausal status (pre-, peri-, post-menopausal) and hormone replacement therapy 138 
(HRT) use at time of blood collection (yes/no). In the present study, cases and controls were 139 
both included in the analyses as the subjects were all cancer-free at blood collection. Out of 140 
the total 349 subjects, 7 subjects (3 cases and 4 controls) had too little serum volume for 141 
NMR spectral acquisition with sufficient sensitivity; 6 additional control subjects were 142 
excluded following the exclusion of their corresponding case subject. The final analysis 143 
included 114 HCC cases and 222 matched controls of which 108 case–control sets with two 144 
matched control subjects and 6 sets with one matched control subject. 145 
NMR spectra acquisition. Sera were processed using standard procedure for 1H NMR 146 
metabolic measurement and profiling protocols [14]. Details on the sera sample preparation as 147 
well as NMR data acquisition and processing have been described elsewhere [15]. In brief, 148 
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each spectrum was reduced to 8,500 bins of 0.001 ppm width over the chemical shift range of 149 
0.5 to 9 ppm. Spectra were normalized to total intensity, centred and Pareto scaled, and 150 
additionally normalized for batch-effects using the batch profiling calibration method [16]. 151 
After removal of the structured noise (characterized by a specific mean and standard 152 
deviation) located in a well-known noise region (8.5-9ppm) and variables with identical 153 
characteristics, the statistical recoupling of variables (SRV) [17], a bucketing procedure, was 154 
applied to the metabolomic spectra. The SRV procedure identifies clusters of variables with 155 
respect to the ratio of covariance and correlation between consecutive variables along the 156 
chemical shift axis, allowing the restauration of the spectral dependency and the recovery of 157 
complex NMR signals corresponding to potential physical, chemical or biological entities. 158 
More details on the SRV procedure are available in the Mathematical Appendix. This 159 
permitted a reduction of the number of NMR variables from 8,500 bins to 285 clusters of 160 
variables corresponding to reconstructed peak entities which constituted the Y-set of 161 
metabolic variables. All steps to obtain the data were done without knowledge of the case-162 
control status of the subjects. Quality control (QC) samples were included to ensure 163 
reproducibility of the NMR data acquisition. 164 
Metabolite identification. The assignment of NMR signals observed in the 1H one-165 
dimensional fingerprints to metabolites has been achieved by the analysis of additional 2D 166 
NMR experiments 1H-13C HSQC and 1H-1H TOCSY obtained on a subset of representative 167 
samples (one control and one case). The measured chemical shifts were compared to 168 
reference shifts of pure compounds using HMDB [18], MMCD [19] and ChenomX, 169 
(ChenomX NMR suite, ChenomxInc, Edmonton, Canada) databases. 170 
Lifestyle variables. The predictors (what will be referred to later on as the X-set) included 13 171 
dietary variables from main EPIC food groups compiled from validated country-specific food 172 
frequency questionnaires (FFQ) [11,20] (potatoes and other tubers; vegetables; legumes; 173 
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fruits, nuts and seeds; dairy products; cereal and cereal products; meat and meat products; fish 174 
and shellfish; egg and egg products; fat; sugar and confectionary; cakes and biscuits; non-175 
alcoholic beverages), alcohol average lifetime intake (continuous, g/day), anthropometric 176 
measures including body mass index (continuous, kg/m2) and height (continuous, cm) that 177 
were measured by trained interviewers in the majority of participants [11], highest level of 178 
education achieved (categorical: none or primary school completed, technical/professional 179 
school, secondary school, longer education (incl. university degree), unspecified), smoking 180 
status (categorical: never, former, current smoker, unknown), a measure of physical activity 181 
(continuous, metabolic equivalents of task (MET)/h), hepatitis status (yes/no, from biomarker 182 
measures of HBV and HCV seropositivity [ARCHITECT HBsAg and anti-HCV 183 
chemiluminescent microparticle immunoassays; Abbott Diagnostics, France]) and baseline 184 
self-reported diabetes status (yes/no). Descriptive information on these variables can be found 185 
in Supplementary table 1. 186 
Statistical analysis 187 
PC-PR2 analysis. Principal component partial R-square (PC-PR2) was primarily used to 188 
identify and quantify sources of systematic variability within metabolomic data [15]. PC-PR2 189 
combines aspects of principal component analysis (PCA) and the R2partial statistic in multiple 190 
linear regression, and allows for (some) inter-correlation between the explanatory variables 191 
under scrutiny [15]. In short, PCA is performed on the 285 clusters of 1H NMR variables and 192 
a number of components is retained explaining an amount of total variability above a 193 
designated threshold (here, 80%). Then, multiple linear regression models are fitted where 194 
each component’s variability is explained in terms of relevant covariates, e.g. specific 195 
characteristics of samples like country of origin, smoking status, laboratory treatment, etc. For 196 
each given component, the R2partial statistic is computed for all covariates, quantifying the 197 
amount of variability each independent variable explains, conditional on all other covariates 198 
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included in the model. Finally, an overall R2partial is calculated as a weighted average for every 199 
covariate, using the eigenvalues as components’ weights. Mathematical details pertaining to 200 
the PC-PR2 method are described elsewhere [15]. 201 
In this study, PC-PR2 was applied to the 285 clusters of NMR variables, whereas the 202 
explanatory variables examined for systematic variability were NMR batch, country of origin, 203 
sex, age at blood collection, serum clot contact time (centrifugation at the day of blood 204 
collection d, or the following day, d+1), length of freezing time (<= 15 vs. >15 years), and 205 
fasting status at blood collection (< 3, 3-6, > 6 hours). With the similar motivation of 206 
identifying sources of variability within lifestyle data, a similar PC-PR2 analysis was applied 207 
to the 21 lifestyle factors; the examined covariates for systematic variability were country of 208 
origin, sex and age at recruitment. For both metabolomics and lifestyle data, residuals on the 209 
variable accounting for most variability, identified through PC-PR2 analyses, were computed 210 
in a series of univariate linear regression models [21] and were used in the subsequent PLS.  211 
PLS analysis. A PLS model was used to relate lifestyle variables to metabolomic profiles. 212 
PLS is a multivariate technique that generalizes features of PCA and multiple linear 213 
regression. PLS iteratively extracts linear combinations of, in turn, predictors (the X-set) and 214 
responses (the Y-set), which in this study, were lifestyle variables and metabolomic profiles, 215 
respectively. First, components or latent factors are extracted allowing a simultaneous 216 
decomposition of the X- and Y-sets, in order to maximize their covariance [22]. The factors 217 
extracted from the predictors’ set are orthogonal. Computational details of PLS are described 218 
in the Mathematical Appendix. As a standard step for the PLS algorithm, the X- and Y-sets 219 
were centered and standardized for the analysis and a simple expectation-maximization (EM) 220 
algorithm, adapted from the PLS kernel algorithm [23,24], was used to compute covariance 221 
matrices when missing values were present in the lifestyle data. This was done as follows: a 222 
first pass of PLS was computed filling in the missing values by the average of the non-223 
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missing values for each corresponding variable. A second pass was then performed whereby 224 
the missing data were assigned their predicted values based on the first model, and the PLS 225 
regression is recomputed. 226 
Then, a seven-fold cross validation analysis was carried out to select the number h of 227 
significant PLS factors to retain [8] (see Mathematical appendix).This was achieved by 228 
splitting the data into seven groups of observations. In turn, each group of observations was 229 
considered as the test set, whilst the other six were the training sets, used to perform PLS 230 
analysis. A measure of PLS performance was determined for each step through the predicted 231 
residual sum of squares (PRESS) statistic, whereby the predicted values in the test set, the Ỹh 232 
matrix, based on the X-components estimated through the model in the training set, were 233 
compared to the observed responses, the Y matrix. This comparison is quantified by the 234 
squared Euclidean distance between these two matrices. In turn for an increasing number h of 235 
components, the process is iterated seven times, until each group of observations serves as a 236 
test set. Eventually, the number h of selected PLS factors is the one minimizing the PRESS 237 
statistic. 238 
For each PLS factor, loadings were computed for the lifestyle (X-set) and the NMR (Y-set) 239 
variables. The loadings, i.e. coefficients quantifying the contribution of each original variable 240 
to the PLS factor, were used to characterize the various factors. As the analysis involved 241 
many variables in the X-set and, particularly, in the Y-set, the interpretation focused primarily 242 
on variables with loading values lower than the 10th percentile and larger than the 90th 243 
percentile for the X variables, and lower than the 5th and larger than the 95th percentiles for the 244 
Y variables, that were deemed the most significant contributors to the PLS factor.  245 
Logistic regression analysis. Last, scores of each PLS factor were related to HCC risk in 246 
conditional logistic regression models to compute HCC odds ratios (ORs) and associated 95% 247 
confidence intervals (95% CI) where ORs express the change in HCC risk associated to one 248 
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standard deviation (1-SD) increase in the score. Models were adjusted for C-reactive protein 249 
concentration, alpha-fetoprotein concentration and for a composite score indicative of liver 250 
damage. The score summarizes the number of abnormal values of circulating enzymes 251 
measured in the hepatic tissue in six liver function tests (alanine aminotransferase >55 U/L, 252 
aspartate aminotransferase >34 U/L, gamma-glutamyltransferase: men>64 U/L and 253 
women>36 U/L, alkaline phosphatase >150 U/L, albumin<35 g/L, total bilirubin>20.5 254 
μmol/L; cut-points were provided by the clinical biochemistry laboratory that conducted the 255 
analyses and were based on assay specifications) [25]. These biomarkers were measured on 256 
the ARCHITECT c Systems™ and the AEROSET System (Abbott Diagnostics) using 257 
standard protocols. Laboratory analyses were performed at the Centre de Biologie République 258 
laboratory, Lyon, France. These adjustments were deemed necessary to address potential 259 
confounding stemming from metabolic disorders, inflammation or underlying liver 260 
dysfunction [25–28]. Adjustments for total dietary fibre, vitamin D, calcium and iron intakes 261 
(continuous) were evaluated but not retained in the final models for lack of confounding 262 
exerted by these variables. The receiver operating characteristic (ROC) curve and the 263 
associated area under the curve (AUC) were determined from conditional logistic regressions 264 
to evaluate the predictive performance of PLS models. AUC values were computed for 265 
conditional logistic models including progressively the PLS scores, separately for lifestyle 266 
and metabolomic factors (as shown in Table 4, column 1). The sensitivity, specificity and 267 
accuracy were calculated for a cut-off point, selected as the minimal distance between the 268 
ROC curve and the upper left corner of the diagram [29,30]. The corrected positive predictive 269 
value (PPV), taking into account the nested case-control design [31,32] was computed by 270 
including the prevalence of HCC in the EPIC population(π= 0.0004), computed over a 7-year 271 
period (1992-2010) where 191 HCC cases were ascertained from a total of 477,206 272 
participants included for case identification after relevant exclusions [33]. The AUC 273 
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unavoidably increases with the number of covariates added to the conditional logistic model. 274 
To address this issue, a resampling scheme was devised to compute an objective/ unbiased 275 
estimate of the AUC, inspired by the work of Uno et al [34]. For each one of the 1000 drawn 276 
bootstrap samples, a 10-fold cross-validation was performed, repeated ten times to remove 277 
variation due to random partitioning of data and to yield more stable estimates. The predicted 278 
values from each of the conditional logistic models in the training set were used to derive 279 
AUC values in the test set. The 2.5th and 97.5th percentile values made up the 95% confidence 280 
intervals.  281 
Sensitivity analyses. A sensitivity analysis was performed by running PLS on data excluding 282 
sets where cases were diagnosed within the first two years of follow-up. The model was 283 
conducted on 271 observations (92 cases, 179 controls), to investigate the performance of the 284 
PLS model, ruling out potential reverse causation. The metabolomic profiles of HCC cases 285 
diagnosed within two years from enrolment could reflect the presence of the tumour rather 286 
than informing about tumour aetiology. The variable importance in the projection (VIP) 287 
statistic was used to facilitate the comparison of the sensitivity analysis with the main 288 
analysis. The VIP expresses the explanatory power of a predictor variable X across all 289 
response variables Y (see Mathematical Appendix). 290 
Mediation analysis. The mediating role of the Y-scores in the association between lifestyle 291 
profiles and HCC risk was assessed. Separately for each extracted combination of lifestyle 292 
and metabolomic PLS factors, mediation analyses were performed with the ‘paramed’ Stata 293 
function that allows for exposure-mediator interaction based on Valeri and VanderWeele’s 294 
work [35]. Briefly, mediation was computed using a Baron and Kenny approach adapted to 295 
dichotomous outcomes [36], where two models were specified. In the mediator model, the 296 
mediator (the Y-score) was linearly regressed on the exposure (the X-score), while in the 297 
outcome model the exposure (X-score) and the mediator (Y-score) were related to the HCC 298 
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indicator in unconditional logistic regressions. Both models accounted for the concentration 299 
of C-reactive protein, alpha-fetoprotein and the composite score of liver damage, and 300 
additionally accommodated the other extracted metabolic profiles (Y-scores) to control for 301 
mediator-outcome confounders that may occur when estimating the Natural Indirect Effect 302 
(NIE) [35]. As the outcome (HCC) is rare, direct and indirect effects can be estimated taking 303 
into account the case-control design. This is done by using the same formulas for the effects, 304 
while running the mediator regression only for the controls [36]. As mediation packages do 305 
not yet accommodate conditional logistic models, the outcome and the mediator models, 306 
which were accommodated in unconditional logistic regressions, were adjusted for center and 307 
age at blood collection for sake of consistency with previous steps of the analysis.  308 
Statistical analyses were performed using R [37] and SAS [38] in general, with the following 309 
packages for specific purposes: PROC PLS in SAS 9.4 for PLS analyses, ‘paramed’ in Stata 310 
12 [39] for mediation analyses, ‘OptimalCutpoints’ in R for ROC-related assessments.  311 
The different steps of the analytical framework developed in this study to model the MITM 312 
are presented in Figure 1.  313 
Results 314 
In the PC-PR2 analyses, a total of 17 and 14 principal components were retained to 315 
explain an amount of total variability exceeding 80% in metabolomics and lifestyle data 316 
respectively. Figure 2 shows that the ensemble of explanatory variables accounted for 19.4% 317 
and 26.7% of total variance, respectively in metabolomics and lifestyle data, of which the 318 
highest contributor was ‘country of origin’ with consistently 8% and 22%.  PLS analysis was 319 
carried controlling for this variable. 320 
After a seven-fold cross-validation, three PLS factors were retained accounting for 321 
21.7% and 8.5% of the overall variability observed in predictor and response variables, 322 
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respectively (Table 1). Lifestyle variables and clusters of NMR variables contributing highly 323 
to PLS factors were identified using factor loading values (Table 2). The first PLS factor was 324 
predominantly positively associated with dairy products and cakes and biscuits intake, while 325 
lifetime alcohol intake, smoking status and diabetes displayed negative loadings for this 326 
lifestyle component (Table 2). On the same PLS factor, signals mainly associated with 327 
glucose and bonds of lipids with negative loading values, and with aspartate, glutamine and 328 
lysine with positive loadings emerged on the metabolomic profile (Table 2). Lifestyle 329 
variables characterizing the second PLS factor included cereal products, height and education 330 
level with negative loadings, and hepatitis with positive loadings. The metabolic signature 331 
included NMR variables with positive loadings associated with aromatic amino acids 332 
(phenylalanine, tyrosine) and glucose; and those with negative loadings associated mainly 333 
with bonds of lipids, threonine and mannose (Table 2). The third PLS factor had a lifestyle 334 
pattern outlining intake of vegetables (high negative loadings values), lifetime alcohol 335 
consumption, smoking, and hepatitis infection (positive loadings). Its counterpart NMR 336 
pattern highlighted signals of glucose and aspartate, with high negative loadings, along with 337 
signals of ethanol, myo-inositol, proline and glutamate as prominent metabolites with positive 338 
loadings (Table 2). 339 
Conditional logistic regression models relating HCC risk with the X- and Y-scores are 340 
shown in Table 3. The first PLS factor was associated to a non-significant decreased HCC 341 
risk (23% and 4% in the X- and Y-scores respectively), while the second and third factors 342 
were associated to a statistically significant increased HCC risk (54% and 11%; and 37% and 343 
22% respectively). Results for the ROC curves parameters are reported in Table 4, including 344 
AUC, sensitivity, specificity, accuracy and PPV for different combinations of the X- and Y-345 
scores. The AUC of the X-scores and Y-scores for all 3 PLS factors, adjusted for C-reactive 346 
protein concentration, alpha-fetoprotein concentration and the score of liver damage, was 347 
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respectively 0.859 and 0.853. An increase in the resampled cross-validated AUC values was 348 
also observed for all three X- and Y-scores, albeit smaller, with respectively 0.836 and 0.827. 349 
Results from the sensitivity analysis conducted on data excluding sets where cases were 350 
diagnosed within the first two years of follow-up, showed similarities in terms of lifestyle 351 
variables’ and metabolites’ loadings on the PLS factors (Supplementary Table 2). Notable 352 
differences pertained to the identification of new signals for the first PLS factor including 353 
ethanol, histidine and an unknown compound. On the second lifestyle factor, BMI (positive 354 
loadings) replaced education level (negative loadings) while the reflected metabolomic profile 355 
was comparable to its counterpart from the main analysis (Supplementary Table 2). On the 356 
third factor, smoking status and hepatitis (positive loadings) were replaced by sugar and 357 
confectionary intake (negative loadings); signals contributing to the associated metabolic 358 
profile remained the same but the direction of the association was inversed as loadings had 359 
opposite signs as compared to the counterpart PLS factor of the main model (Supplementary 360 
Table 2). Corresponding ORs from conditional logistic regression models relating the X- and 361 
Y-scores to HCC risk are available in Table 5. The scores showed a statistically significant 362 
association in the second factor for both sets and in the third factor for the Y-set. ROC-363 
associated statistics for different models are presented in Supplementary Table 3. The VIP 364 
plot (Figure 3) displayed the results for the importance of the lifestyle variables in the 365 
prediction of the Y-set computed for the main PLS model performed including all subjects 366 
(panel A) and for the sensitivity model (panel B). The results suggested a potential gain in 367 
stability as prominent lifestyle variables for prediction were maintained 368 
(hepatitis/diabetes/cakes and biscuits), the magnitude of the VIP was improved for some 369 
(fat/lifetime alcohol intake) and less emphasis was put on others (BMI/physical activity). 370 
Finally, the natural indirect effect was assessed in the mediation analyses and the results are 371 
presented in Table 6. Overall, there was limited evidence that metabolomic signals mediated 372 
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the association between lifestyle components and HCC risk in the first PLS factor. Evidence 373 
of a significant mediated effect by the Y-scores was found in the second and third PLS factors 374 
when models were adjusted for exposure-mediator interaction (Table 6).  375 
Discussion 376 
In this work, an analytical strategy based on PLS analysis was conceived to extract 377 
relevant information from sets of lifestyle and NMR metabolomic variables, and to relate the 378 
resulting components to the risk of disease. This offered a way to implement the MITM 379 
approach [6] in a nested case-control study on HCC within the EPIC study. MITM has been 380 
suggested as a way to link specific putative metabolites to lifestyle exposures and disease 381 
outcomes, thus leading to the identification of potential intermediate biomarkers [6].  382 
An implementation of MITM was previously carried out in a nested case-control study 383 
in the Turin sub-cohort of EPIC [7] based on prospectively collected plasma samples from a 384 
pilot study on colon and breast cancers. In their work, a list of intermediate markers was 385 
identified by an in-parallel evaluation of the relationships between untargeted 1H NMR 386 
profiles with dietary exposures and risk of colon and breast cancers using correlation analysis 387 
and logistic regression. In our study, a different analytical framework was developed, largely 388 
exploiting features of PLS analysis, a multivariate technique that iteratively extracts 389 
components capturing co-variability in sets of predictors and response variables [8,40]. A set 390 
of lifestyle predictor variables were related to NMR responses. In a second step, PLS 391 
predictors’ and responses’ scores were linked to the risk of HCC.  392 
Another sensitive issue in this analysis was the choice of lifestyle variables. Two 393 
disease-indicator variables reflecting environmental exposures, diabetes and hepatitis, were 394 
included in the set of predictors, as they turned out to have an important role in the 395 
characterization of metabolomic signatures. In addition, diabetes is the main metabolic risk 396 
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factor for HCC alongside with fatty liver disease [41,42], and chronic infection with hepatitis 397 
B (HBV) and particularly hepatitis C (HCV) viruses were classified as class I carcinogens for 398 
HCC by IARC [43].  399 
Other relevant biomarkers were not part of the list of predictors in PLS analysis, but were 400 
controlled for in logistic regression models. This included C-reactive protein, alpha-401 
fetoprotein, and a score for liver damage,  an index of different circulating enzymes measured 402 
in the hepatic tissue indicating potential underlying liver function impairment [25]. The alpha-403 
fetoprotein was included as an adjustment factor in the analyses not because of its established 404 
part as a serum marker for HCC diagnosis [26,44], but rather to account for it as a potential 405 
confounder that may cloud the relation between scores and HCC, both in conditional logistic 406 
regressions and in mediation analyses. 407 
Similarly to other multivariate techniques, a key aspect of PLS analysis is the choice 408 
of the number of factors to retain, in an effort of exhaustively summarizing data variability 409 
through a limited number of factors. Based on a seven-fold cross-validation, three linear 410 
combinations of variables were extracted in this work. A challenging aspect of this analysis is 411 
the interpretation of these factors, with respect to lifestyle and metabolomic variables. A 412 
subjective criterion based on the distribution of loading values was used throughout. The 413 
variables displaying the most extreme loading values (in absolute terms) were the ones 414 
characterizing each factor.  415 
The first lifestyle factor highlighted a healthy pattern with negative loadings for 416 
diabetes status, smoking status and lifetime alcohol intake, and was not associated to HCC 417 
risk, similarly to its metabolomics counterpart. The lifestyle component of the second PLS 418 
factor, was reflective of a lifestyle pattern reflective of “higher-risk exposures”, and was 419 
related to a significant 54% increase in HCC risk. Likewise, its associated metabolic 420 
component displayed a significant HCC risk augmentation by 11%. The lifestyle component 421 
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of the third PLS factor described participants with lower vegetables intake, elevated lifetime 422 
alcohol consumption, more likely to be ever smokers and hepatitis positive; one standard 423 
deviation increase of this component was associated to a statistically significant 37% increase 424 
in HCC risk. Similarly, a 22% significant increase in HCC risk was observed for its metabolic 425 
counterpart, characterized by positive signals of ethanol and myo-inositol, and displayed 426 
negative loadings for glucose.  427 
The MITM is captured by the rationale of PLS analysis, in the sense that each set of lifestyle 428 
profiles and metabolic signatures of the extracted PLS factors mirrored one another. In 429 
addition, mediation was observed for the second and third PLS factors, whereby the 430 
metabolomic component mediated the relation between the lifestyle component and HCC, for 431 
which statistically significant associations with HCC risk were estimated, emphasising the 432 
presence of a MITM. Mediation analysis relies on the assumption that there is no mediator-433 
outcome confounder that is affected by the exposure [35]. In our study C-reactive protein, 434 
alpha-fetoprotein and liver damage score were weakly correlated to lifestyle factor score, thus 435 
introducing potential bias in the estimation of direct and indirect effects in our mediation 436 
analysis. Additionally, a number of background confounders (mediator-outcome and 437 
exposure-outcome confounders) were present that we have tried to control for, either by 438 
adjustments or by accounting for potential interactions, however some degree of bias can 439 
remain and caution should be employed when interpreting the results. 440 
The predictive performance of PLS factors in relation to HCC occurrence was evaluated 441 
through an analysis of AUC values. The performance of the model improved progressively, 442 
with all 3 X- and Y-scores added; after a bootstrapped cross-validation, the AUC estimates 443 
were lower  but the increase in the performance was nevertheless present. The ROC 444 
methodology allows estimation of PPV, which expresses the risk of disease after a positive 445 
test [45]. In a setting with low HCC prevalence (π=0.0004), in line with Western populations 446 
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[46], extremely low PPV estimates were observed. In the absence of a very specific test, many 447 
positive tests arise from disease-free individuals [45], thus leading to a dilution of PPV. 448 
A sensitivity analysis was carried out excluding the first two years of follow-up, but results 449 
were virtually unchanged, both in terms of relative risk estimates in logistic regression 450 
models, and of percentage of variability explained in PLS analysis. These findings suggest 451 
that reverse causation bias, if present, was minimal. 452 
This study had the ambition of integrating in the same analytical framework study 453 
participants’ lifestyle characteristics with a large number of NMR metabolic profiles. These 454 
data pose a number of methodological challenges due to their size and the complexity of 455 
exhaustively capturing and interpreting the biological processes they reflect. To address these 456 
issues, techniques involving multivariate statistics have been progressively revived in the 457 
recent years [2]. Epidemiologic evaluations of metabolomic data frequently combined PLS 458 
with discriminant analysis, such as PLS-DA or O-PLS-DA. The main objective of these 459 
methods is to identify a series of metabolomic features distinguishing between two very 460 
distinct groups of study participants [47,48]. In such strategies, only one set of variables is 461 
multi-dimensional and the response is one variable only. Similar multivariate techniques for 462 
pattern extraction, belonging to the family of regression methods, include reduced rank 463 
regression. This multivariate method relates an ensemble of response variables to a set of 464 
predictor variables where the estimated matrix of the regression coefficients is of reduced 465 
rank [49–51]. In addition, canonical correlation analysis (CCA) [52] is a method applied to 466 
identify the optimum structure or dimensionality of each variable set that maximizes the 467 
relationship between two sets of multi-dimensional variables. The main difference between 468 
CCA and PLS regression is that CCA maximizes the correlation between the two new 469 
dimensions, i.e. extracted factors, whereas PLS maximizes their covariance. PLS can be 470 
considered as a trade-off  between CCA and PCA, since maximizing the covariance 471 
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corresponds to maximizing the product of the correlation and standard deviation, given that 472 
cov(X,Y)=cor(X,Y)*SD(X)*SD(Y). 473 
Untargeted NMR was used in this work to acquire metabolomic signals. Prior to PLS 474 
analysis, a bucketing procedure, the statistical recoupling of variables (SRV) [17,53], was 475 
applied to reduce the number of NMR variables to 285 clusters. This was done by aggregating 476 
consecutive NMR bins based on their covariance to correlation ratio. This allowed the 477 
identification of informative components of the spectra, thus acting as an efficient noise-478 
removing filter. Subsequently the annotation effort remains challenging, for a number of 479 
reasons. The majority of published metabolomics studies often identified a limited number of 480 
metabolites at a time [54], and the Human Metabolome Database (HMDB) and other related 481 
resources [18,55], that offer richly annotated information continuously increasing the 482 
metabolite coverage for users, are mostly exploited through time consuming interactive 483 
procedures. In addition, individual metabolites often overlap in NMR signals, which can 484 
hinder annotations. These challenges, as well as large variability in metabolite concentrations, 485 
and disentangling informative signals from noise, are not specific to NMR and pertain to any 486 
type of untargeted technique. Such investigations may profit from complementary targeted 487 
metabolomic analytical strategies [55].  488 
Throughout the different steps of this work, the scaling problem was first tackled by 489 
normalizing spectra to total intensity. NMR data were also centered and Pareto-scaled, 490 
together with correction for potential batch effects [16]. The PC-PR2 method offered a way to 491 
investigate major sources of systematic variability in NMR and lifestyle data [15]. The 492 
variable “country of origin” emerged as the variable accounting for the largest proportion of 493 
total variability, and the residual method was used to control for this variable in the following 494 
steps of the analysis. While this may lead to removing regional gradients of dietary 495 
variability, this step is instrumental to avoid unwanted systematic regional-specific bias in the 496 
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data in country-specific questionnaire assessments. In addition, technical aspects like storage 497 
and handling of biological samples, fasting status at blood collection are specific to each 498 
country [15]. In any case, variability due to “country of origin” is not exploited in conditional 499 
logistic models, as cases and controls were also matched on center. 500 
One of the limitations of this study is the restricted sample size which raises concerns 501 
with regards to power to detect associations. While a larger sample size would possibly result 502 
in more statistically significant findings, we used the data that was available with NMR 503 
profiles measured. In this work we have developed a framework to analyse complex data 504 
integrating lifestyle and metabolomics in relation to risk of disease. The approach described in 505 
this study has merits but also pitfalls among which it is worth mentioning that statistical 506 
methods are used repeatedly on the same set of data, notably the PLS model, the conditional 507 
logistic regression, the AUC estimation and mediation analysis. To partially address this, a 508 
cross-validation approach was devised for AUC estimation which involved conditional 509 
logistic regression, whereby PLS was done without knowledge of the case/control status. 510 
However, conditional logistic regression models and mediation analyses were implemented 511 
on the same data, and our analysis did not account for this limitation. This may have led to 512 
spuriously increase the nominal level of statistical significance of statistical tests.  513 
Conclusion 514 
The MITM emerged as a method for the identification of relevant biomarkers, with 515 
great potential to unravel utmost important steps in the aetiology of disease. The analytical 516 
strategy for MITM was developed to use all potentially informative aspects of high-517 
throughput data by integrating metabolomic, dietary and lifestyle exposures together with 518 
disease indicators. While the framework was applied towards the investigation of HCC 519 
determinants, it can be easily extended to similar aetiological contexts and applied to other –520 
omics settings. 521 
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Legends to figures  746 
Figure 1: General scheme of the analytical framework developed in the study. A PC-PR2 747 
analysis is carried out beforehand to identify relevant sources of variation. In the PLS model 748 
the X- and Y- sets are related to each other, and scores are computed (1). X- and Y-scores are, 749 
in turn, associated to a case-control indicator of HCC status in conditional logistic regression 750 
models (2). A mediation analysis is carried out to explore the role of metabolomics in the 751 
association between lifestyle factors and risk of HCC (3). 752 
Figure 2: PC-PR2 analysis results* identifying the sources of variability in the NMR data 753 
(panel A) and in the lifestyle data (panel B). 754 
* 17 and 14 components were retained to account for 80 % (threshold used) of total NMR (A) 755 
and lifestyle variability (B), respectively. The R2 value represents the amount of variability in 756 
NMR / lifestyle variable explained by the ensemble of investigated predictors. 757 
Figure 3: Variable importance plot (VIP) displaying the variable importance for projection 758 
statistic of the predictor variables for the PLS analyses. 759 
Panel A: Results from the main PLS model run on all observations (N=336, X-set=21, Y-760 
set=285). 761 
Panel B: Results from the PLS sensitivity analysis run on a subsample (N=271, 92 cases, 179 762 
controls) excluding sets where cases were diagnosed within the first two years of follow-up 763 
(X-set=21, Y-set=285). 764 
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The horizontal line corresponds to Wold’s criterion (0.8), the threshold used to rule if a 765 
variable has an important contribution to the construction of the Y variables (see 766 
Mathematical Appendix for further details). 767 
31 
 
Table 1: Individual and cumulative variation (%) explained by the first 3 PLS factors in 21 lifestyle (X-set) and 285 
NMR (Y-set) variables. 
# of 
PLS  Lifestyle Variables NMR Variables 
Factors Individual  Cumulative  Individual Cumulative 
1 6.17 - 5.51 - 
2 6.23 12.40 2.38 7.89 
3 9.27 21.67 0.59 8.48 
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Table 2: Lifestyle and NMR cluster variables contributing to each of the 3 PLS factors (N=336, X-set=21, Y-
set=285). 
PLS 
Factor Lifestyle Variable* 
Loading 
value 
CS*‡ 
(ppm) Metabolite** 
Loading 
value 
1 Dairy Products 0.28 5.22 
Glucose 
-0.06 
  Cakes and Biscuits 0.32 3.88 -0.05 
  Lifetime Alcohol Consumption -0.25 3.82 -0.06 
  Smoking Status -0.39 3.76 -0.06 
  Diabetes -0.63 3.71 -0.05 
    3.54 -0.05 
    3.50 -0.07 
    3.48 -0.07 
    3.44 Acetoacetate -0.07 
    3.23 Choline + Glycerphosphocholine  -0.04 
    3.01 Lysine 0.10 
    2.94 Albumin 0.10 
    2.65 Aspartate 0.10 
    2.42 Glutamine 0.10 
    2.28 Acetoacetate 0.10 
    2.22 CH2-CH2-COOC bond of lipids + Acetone -0.04 
    1.86 Lysine 0.09     1.87 0.10 
      1.53 CH2-CH2-COOC bond of lipids  -0.03 
2 Cereal and Cereal Products -0.16 7.17 Tyrosine 0.13   Height -0.34 6.87 0.13 
  Education Level -0.26 5.27 CH=CH bond of lipids -0.13 
  Hepatitis 0.49 5.22 Glucose 0.16 
    5.18 Mannose + Lipid O-CH2  -0.12 
    4.27 Lipid O-CH2 -0.12 
    4.25 Threonine -0.14 
    4.07 Choline + Lipid O-CH2 + Myo-inositol -0.12 
    4.05 Creatinine -0.14 
    3.88 
Glucose 
0.15 
    3.82 0.16 
    3.76 0.15 
    3.71 0.15 
    3.54 0.15 
    3.50 0.16 
    3.48 0.16 
    3.44 Acetoacetate 0.16 
    3.23 Choline + Glycerphosphocholine  0.15 
    2.80 Aspartate -0.12 
    2.22 CH2-CH2-COOC bond of lipids + Acetone -0.11 
    2.19 CH2-CH2-COOC bond of lipids -0.15 
    2.02 Proline  + Glutamate + CH2=C bonds of lipids -0.13 
    1.53 CH2-CH2-COOC bond of lipids  -0.13 
    1.25 CH2 bond of lipids  -0.12 
      0.86 Cholesterol + CH3 bond of lipids -0.12 
3 Vegetables -0.42 7.32 Phenylalanine 0.11 
  Lifetime Alcohol Consumption 0.29 5.22 Glucose -0.13 
  Smoking Status 0.25 4.28 Lipid O-CH2  0.11 
  Hepatitis 0.26 3.88 
Glucose 
-0.11 
    3.82 -0.11 
    3.76 -0.12 
    3.71 -0.11 
    3.69 -0.11 
    3.63 Myo-inositol 0.16 
    3.50 Glucose -0.13     3.48 -0.12 
    3.44 Acetoacetate -0.12 
    3.35 Proline 0.11     3.33 0.13 
    3.28 Myo-inositol 0.12 
    3.23 Choline + Glycerphosphocholine  -0.12 
    2.80 Aspartate -0.13 
    2.76 part of =CH-CH2-CH= bond of lipids  -0.13 
    2.35 Proline + Glutamate 0.12     2.33 0.13 
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    1.20 3-hydroxybutyrate + CH2 bond of lipids  0.11 
    1.16 Ethanol 0.15 
      0.66 Cholesterol 0.11 
*Relevant lifestyle and NMR variables contributing to each PLS factor selected based on their associated loading 
values <10th percentile (pctl) and >90th pctl or <5th pctl and >95th pctl respectively. 
‡ CS: 1H chemical shift (in ppm) of the cluster (center value). 
**Some of the identified clusters were found to be background noise during the annotation phase and were removed 
from this table. 
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Table 3: HCC odds ratios* and 95% confidence interval (OR, 95% CI) associated with the lifestyle (X-set) and the 
NMR clusters (Y-set) PLS scores in the main analysis (N=336, X-set=21, Y-set=285). 
 
PLS Lifestyle Variables 
X-scores 
PLS NMR Variables 
Y-scores 
Factor OR** (95% CI) P-Wald† Factor OR** (95% CI) P-Wald† 
1 0.77 (0.58, 1.02)  0.07 1 0.96 (0.91, 1.01) 0.09 
2 1.54 (1.06, 2.25) 0.02 2 1.11 (1.02, 1.22) 0.02 
3 1.37 (1.05, 1.79) 0.02 3 1.22 (1.04, 1.44) 0.01 
*Models were adjusted for C-reactive protein concentration, alpha-fetoprotein concentration and a composite score for 
liver damage. Cases and controls were matched on age at blood collection (± 1 year), sex, study centre, date (± 2 
months) and time of the day at blood collection (± 3 hours), fasting status at blood collection (<3/3-6/>6 hours); 
among women, additional matching criteria included menopausal status (pre-/peri-/postmenopausal) and hormone 
replacement therapy use at time of blood collection (yes/no). ** ORs expressing the change in HCC risk associated to 
1-SD increase in the score. † Wald's test was for continuous exposure compared with a Chi-square distribution with 1 
degree of freedom (dof). 
 
 
 
Table 4: Area under the curve (AUC), sensitivity, specificity, accuracy and positive predictive value (PPV) of ROC 
models (with 95% CI), from the main PLS analysis (N=336, X-set=21, Y-set=285). 
 
AUC AUCb** Sensitivity Specificity Accuracy PPV 
Adjustment Covariates (ADJ)* 0.842 (0.794, 0.891) 0.821 (0.766, 0.868) 0.752 (0.662, 0.829) 0.802 (0.743, 0.852) 0.785 0.0015 
 
X1 scores + ADJ 0.846 (0.797, 0.894) 0.825 (0.766, 0.875) 0.743 (0.653, 0.821) 0.838 (0.783, 0.884) 0.806 0.0018 
X1+X2 scores + ADJ 0.854 (0.808, 0.900) 0.831 (0.772, 0.881) 0.743 (0.653, 0.821) 0.824 (0.768, 0.872) 0.797 0.0017 
X1+X2+X3 scores + ADJ 0.859 (0.811, 0.907) 0.836 (0.778, 0.887) 0.796 (0.710, 0.866) 0.788 (0.729, 0.840) 0.791 0.0015 
 
Y1 scores + ADJ 0.841 (0.793, 0.890) 0.817 (0.760, 0.865) 0.735 (0.643, 0.813) 0.820 (0.763, 0.868) 0.791 0.0016 
Y1+Y2 scores + ADJ 0.845 (0.795, 0.894) 0.820 (0.762, 0.872) 0.735 (0.643, 0.813) 0.851 (0.798, 0.895) 0.812 0.0020 
Y1+Y2+Y3 scores + ADJ 0.853 (0.804, 0.902) 0.827 (0.771, 0.877) 0.726 (0.634, 0.805) 0.883 (0.833, 0.922) 0.890 0.0025 
*The model is run on the adjustment covariates (ADJ) including the C-reactive protein concentration, alpha-
fetoprotein concentration and a composite score for liver damage. ** AUCb is the bootstrapped-cross validated 
estimate of the AUC. X1, X2 and X3 are the lifestyle component scores of the first, second and third PLS factors, 
respectively. Y1, Y2, and Y3 are the metabolomics component of the first, second and third PLS factors, respectively. 
 
 
Table 5: HCC odds ratios* and 95% confidence intervals (OR, 95%CI) associated with the lifestyle (X-set) and the 
NMR clusters (Y-set) PLS scores. Results from the sensitivity analysis (N=271, 92 cases, 179 controls) conducted 
excluding sets where cases were diagnosed within the first two years of follow-up (X-set=21, Y-set=285). 
 
PLS Lifestyle Variables 
X-scores 
PLS NMR Variables 
Y-scores 
Factor OR** (95% CI) P-Wald† Factor OR** (95% CI) P-Wald† 
1 0.80 (0.60, 1.08) 0.15 1 0.96 (0.94, 1.04) 0.56 
2 1.56 (1.02, 2.40) 0.04 2 1.18 (1.03, 1.36) 0.02 
3 0.86 (0.67, 1.11) 0.26 3 0.86 (0.73, 0.99) <0.05 
*Models were adjusted for C-reactive protein concentration, alpha-fetoprotein concentration and a composite score for 
liver damage. Cases and controls were matched on age at blood collection (± 1 year), sex, study centre, date (± 2 
months) and time of the day at blood collection (± 3 hours), fasting status at blood collection (<3/3-6/>6 hours); 
among women, additional matching criteria included menopausal status (pre-/peri-/postmenopausal) and hormone 
replacement therapy use at time of blood collection (yes/no). ** ORs expressing the change in HCC risk associated to 
1-SD increase in the score. † Wald's test was for continuous exposure compared with a Chi-square distribution with 1 
degree of freedom (dof). 
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Table 6: Results from the mediation analysis (N= 336, X-set=21, Y-set=285): Natural Indirect Effect (NIE) and 
95%CI*. 
 
Model**  Natural Indirect Effect (NIE) 
Exposure 
(A) Mediator (M) Outcome 
A*M 
interaction 
term 
Estimate (95%CI) p-value 
X1 score Y1 score HCC No 0.91 (0.77, 1.06) 0.23 
X2 score Y2 score HCC No 1.11 (0.97, 1.25) 0.12 
X3 score Y3 score HCC No 1.08 (0.94, 1.23) 0.28 
X1 score Y1 score HCC Yes 0.96 (0.79, 1.17) 0.70 
X2 score Y2 score HCC Yes 1.15 (1.01, 1.31) 0.04 
X3 score Y3 score HCC Yes 1.13 (1.01, 1.28) 0.04 
* The standard errors used to compute the 95%CI were obtained using the delta method. 
**Models were adjusted for the C-reactive protein concentration, alpha-fetoprotein concentration and a composite 
score for liver damage, as well as for the other Y-scores, as potential mediator-outcome confounders. Additionally, the 
outcome and the mediator models were adjusted for centre and age at blood collection. 
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Supplementary Tables 
A Statistical framework to model the meeting-in-the-middle principle using metabolomic data: 
application to hepatocellular carcinoma in the EPIC study.  
Supplementary Table 1: Summary statistics of the predictors variables (X-set) of the study subjects in the EPIC liver 
nested case–control study (N=336, 114 Cases, 222 Controls). 
 
  Mean / N* sd / %* p5 p95 N missing 
Dietary Variables (g/day) 
Potatoes and other tubers 100.57 78.15 9.34 266.97 0 
Vegetables 194.20 143.22 45.03 473.45 0 
Legumes 9.85 18.03 0.00 41.18 0 
Fruits, nuts and seeds 232.80 197.94 23.55 585.22 0 
Dairy products 334.40 261.46 49.92 777.48 0 
Cereal and cereral products 227.04 117.67 76.39 458.94 0 
Meat and meat products 115.97 62.29 37.83 236.32 0 
Fish and shellfish 32.88 32.26 3.78 81.43 0 
Egg and egg products 18.67 18.72 1.88 55.57 0 
Fat 34.61 18.48 11.01 70.76 0 
Sugar and confectionary 47.26 51.51 1.93 138.73 0 
Cakes and biscuits 41.33 49.68 0.00 147.26 0 
Non-alcoholic beverages 1053.91 793.31 85.00 2391.90 0 
Anthropometric variables 
BMI (kg/m2) 27.41 4.41 21.22 36.16 0 
Height (cm) 169.70 9.99 152.00 184.80 0 
Lifestyle Variables 
Lifetime alcohol intake (g/day) 23.27 41.38 0 91.998 61 
Physical activity (Mets/h) 77.13 49.45 11.5 173.63 0 
Highest Education Level  
None or primary school completed 167 49.7  -  -  - 
Technical/professional school 75 22.32  -  -  - 
Secondary school 27 8.04  -  -  - 
Longer education (incl. university degree) 62 18.45  -   -  - 
Unspecified or Unknown 5 1.49  -   -  - 
Smoking status 
Never 124 36.9  -  -  - 
Former 125 37.2  -  -  - 
Current smoker 85 25.3  -  -  - 
Unspecified or Unknown 2 0.6  -   -  - 
Pathology variables indicative of lifestyle 
Hepatitis status 1 
No 291 86.87  -  -  - 
Yes 44 13.13  -   -  - 
Diabetes 0 
No 307 91.37  -  -  - 
Yes 29 8.63  -   -  - 
*Mean and standard deviation (sd), were reported for continuous variables and frequencies and percentages (%) were 
reported for categorical variables.  
p5: 5th percentile, p95:95th percentile.
Supplementary Table 2: Results from the sensitivity analysis run on a subsample (N=271, 92 cases, 179 controls) 
excluding sets where cases were diagnosed within the first two years of follow-up (X-set=21, Y-set=285). Lifestyle 
and NMR cluster variables contributing to each PLS factor. 
 
PLS 
Factor Lifestyle Variable* 
Loading 
value 
CS*‡ 
(ppm) Metabolite** 
Loading 
value 
1 Dairy Products 0.33 7.03 Histidine 0.09 
  Cakes and Biscuits 0.34 5.22 
Glucose 
-0.07 
  Lifetime Alcohol Consumption -0.34 3.88 -0.06 
  Smoking Status -0.26 3.82 -0.07 
  Diabetes -0.59 3.76 -0.06 
    3.71 -0.06 
    3.54 -0.05 
    3.50 -0.07 
    3.48 -0.08 
    3.44 Acetoacetate -0.08 
    3.23 Choline + Glycerphosphocholine -0.05 
    3.03 Creatine 0.10 
    3.01 Albumin 0.10 
    2.28 Acetoacetate 0.10 
    2.22 CH2-CH2-COOC bond of lipids + Acetone -0.03 
    2.06 Proline + Glutamate 0.09 
    1.91 Lysine + Arginine -0.03 
    1.87 Lysine 0.09 
    1.16 Ethanol -0.04 
    1.08 Unknown 1 0.09 
      0.91 CH3 bond of lipids 0.09 
2 Cereal and Cereal Products -0.24 7.17 
Tyrosine 
0.14 
  BMI 0.34 6.87 0.14 
  Height -0.39 5.27 CH=CH bond of lipids -0.14 
  Hepatitis 0.55 5.22 Glucose 0.13 
    5.18 Mannose + Lipid O-CH2  -0.13 
    4.27 Lipid O-CH2  -0.12 
    4.25 Threonine -0.14 
    4.05 Creatinine -0.14 
    3.88 
Glucose 
0.13 
    3.82 0.13 
    3.76 0.13 
    3.75 0.12 
    3.71 0.12 
    3.54 0.15 
    3.50 0.13 
    3.48 0.13 
    3.44 Acetoacetate 0.13 
    3.23 Choline + Glycerphosphocholine 0.12 
    2.80 Aspartate -0.13 
    2.76  =CH-CH2-CH= bond of lipids  -0.12 
    2.19 CH2-CH2-COOC bond of lipids -0.16 
    2.02 Proline + Glutamate -0.14 
    1.53 CH2-CH2-COOC bond of lipids  -0.13 
    1.25 CH2 bond of lipids  -0.12 
      0.86 Cholesterol + CH3 bond of lipids -0.12 
3 Vegetables 0.39 5.25 Glucose 0.17 
  Sugar and Confectionnary -0.21 4.28 Lipid O-CH2  -0.07 
  Lifetime Alcohol Consumption -0.29 4.14 Proline -0.08 
    4.07 Choline + Lipid O-CH2 + Myo-inositol -0.07 
    3.88 
Glucose 
0.16 
    3.82 0.16 
    3.76 0.16 
    3.75 0.14 
    3.71 0.15 
    3.69 0.16 
    3.63 Myo-inositol -0.16 
    3.54 
Glucose 
0.12 
    3.50 0.17 
    3.48 0.17 
    3.44 Acetoacetate 0.16 
    3.41 
Proline 
-0.10 
    3.35 -0.15 
    3.34 -0.12 
    3.28 Myo-inositol -0.09 
    3.23 Choline + Glycerphosphocholine 0.15 
    1.91 Lysine + Arginine -0.07 
    1.16 Ethanol -0.16 
    0.68 Cholesterol -0.06 
      0.66 -0.08 
*Relevant lifestyle and NMR variables contributing to each PLS factor selected based on their associated loading 
values <10th percentile (pctl) and >90th pctl or <5th pctl and >95th pctl respectively. 
‡ CS: 1H chemical shift (in ppm) of the cluster (center value). 
**Some of the identified clusters were found to be background noise during the annotation phase and were removed 
from this table. 
 
 
Supplementary Table 3: Results from the sensitivity analysis (N=271, 92 cases, 179 controls) conducted excluding 
sets where cases were diagnosed within the first two years of follow-up (X-set=21, Y-set=285). Area under the curve 
(AUC), sensitivity, specificity, accuracy and positive predictive value (PPV) of ROC models (with 95% CI). 
 
  AUC AUCb** Sensitivity Specificity Accuracy PPV 
Adjustment Covariate (ADJ)*  0.846 (0.793, 0.899) 0.827 (0.765,0.879) 0.750 (0.649, 0.834) 0.838 (0.776, 0.889) 0.808 0.0018 
 
X1 scores + ADJ 0.853 (0.800, 0.905) 0.834 (0.774, 0.890) 0.728 (0.626, 0.816) 0.872 (0.813, 0.917) 0.823 0.0023 
X1+X2 scores + ADJ 0.860 (0.811, 0.910)  0.837 (0.772, 0.893) 0.750 (0.649, 0.834) 0.832 (0.769, 0.884) 0.804 0.0018 
X1+X2+X3 scores + ADJ 0.861 (0.810, 0.912)  0.837 (0.773, 0.893) 0.761 (0.661, 0.844) 0.838 (0.776, 0.889) 0.812 0.0019 
 
Y1 scores + ADJ 0.847 (0.794, 0.900) 0.827 (0.768, 0.884) 0.739 (0.637, 0.825) 0.838 (0.776, 0.889) 0.804 0.0018 
Y1+Y2 scores + ADJ 0.848 (0.794, 0.901)  0.827 (0.764, 0.883) 0.717 (0.614, 0.806) 0.899 (0.846, 0.939) 0.838 0.0028 
Y1+Y2+Y3 scores + ADJ 0.853 (0.800, 0.907) 0.826 (0.763, 0.882) 0.717 (0.614, 0.806) 0.911 (0.859, 0.948) 0.845 0.0032 
*The model is run on the adjustment covariates (ADJ) including the C-reactive protein concentration, alpha-
fetoprotein concentration and a composite score for liver damage. ** AUCb is the bootstrapped-cross validated 
estimate of the AUC. X1, X2 and X3 are the lifestyle component scores of the first, second and third PLS factors, 
respectively. Y1, Y2, and Y3 are the metabolomics component of the first, second and third PLS factors, respectively. 
 
